Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Rheumatology | Musculoskeletal
Clinical Trials: Rheumatoid Arthritis
A listing of clinical trials currently looking for volunteers to enroll in Rheumatoid Arthritis studies. Click on the closest city to find more detailed information on a research study in your area.
Alabama
Anniston : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Anniston : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Anniston : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Anniston : Investigational Site Number 840070 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Birmingham : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
View More »
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Birmingham : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Birmingham : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Huntsville : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Huntsville : Pfizer Investigational Site
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Huntsville : Site Reference ID/Investigator# 38982
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Huntsville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Huntsville : 170
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Huntsville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Huntsville : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Huntsville : Rheumatology Associates Of North Alabama, P.C.
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Mobile : Mobile Diagnostic Center Rheumatology
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Mobile : 180
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Tuscaloosa :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Tuscaloosa : Site Reference ID/Investigator# 38686
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Tuscaloosa : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Arizona
Paradise Valley : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Paradise Valley : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Scottsdale : Radiant Research - Scottsdale
Rheumatoid Arthritis (RA) Research Study
View More »
Gilbert :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Gilbert : Investigational Site Number 840072 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Glendale : 247
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Glendale : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Glendale : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Glendale : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mesa : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Mesa : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Mesa : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Mesa : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mesa : 166 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Paradise Valley : Site Reference ID/Investigator# 37983
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Paradise Valley : Site Reference ID/Investigator# 42044
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Paradise Valley : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Paradise Valley : 234
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Paradise Valley : 165
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Paradise Valley : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Paradise Valley : 154 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Peoria : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Peoria : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Peoria : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Peoria : Sun Valley Arthritis Center, Ltd
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Phoenix : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Phoenix : 243
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Phoenix : 187
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Phoenix : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Phoenix : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Phoenix : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Phoenix : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Scottsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Scottsdale : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Scottsdale : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Scottsdale : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Scottsdale : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Scottsdale : 118 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tucson :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Tucson :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tucson : Tucson Orthopaedic Research Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Tucson : University of Arizona
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Tucson : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tucson : 159
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Arkansas
Hot Springs : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Jonesboro : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Jonesboro : NEA Baptist Clinic - Clinical Research Center
If you have RA and have had an inadequate response to a TNF-a inhibitor, contact us today!
View More »
Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hot Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hot Springs : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hot Springs : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hot Springs : 103 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Hot Springs : 152
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Jonesboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Little Rock : Site Reference ID/Investigator# 44823
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Little Rock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Little Rock : 156
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Little Rock : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
California
La Jolla : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Los Angeles : University of California, Los Angeles Updated
A research study examining the effects of milnacipran for the treatment of pain in older adults with rheumatoid arthritis
Los Angeles : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
P Hemet : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Palo Alto : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Sacramento : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
San Diego : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
San Luis Obispo : Coastal Medical Research Group, Inc.
Have you been diagnosed with Oseoarthritis or Rheumatoid Arthritis?
Santa Maria : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Wildomar : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Covina : 160
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Covina : 127 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Covina : 147
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Encino : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Escondido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Hemet : Site Reference ID/Investigator# 37981
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Hemet : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hemet : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Huntington Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Huntington Beach : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Huntington Beach : 164
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Huntington Beach : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Huntington Beach : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Inglewood : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
La Jolla : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
La Jolla : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
La Jolla : 148 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
La Jolla : University of California, San Diego
OTIS Autoimmune Diseases in Pregnancy Project
La Jolla : University of California, San Diego
OTIS Autoimmune Diseases in Pregnancy Project
La Jolla : Scripps Clinic
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
La Mesa :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
La Mesa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lakewood :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Loma Linda : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Long Beach : Site Reference ID/Investigator# 40208
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Long Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Long Beach : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Long Beach : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Long Beach : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Long Beach : 184 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Los Alamitos : Trial Concierge/Pacific Clinical Studies
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Los Angeles : Axis Clinical Trials
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Los Angeles : 159
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Los Angeles : UCLA Semel Institute
Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis
Los Angeles : 149
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Menifee : 144
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Murrieta : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Palm Desert :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Palm Desert : Desert Medical Advances
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Palo Alto : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Palo Alto : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Palo Alto : 104 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Sacramento : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sacramento : Site Reference ID/Investigator# 38423
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Sacramento : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
San Diego :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
San Diego : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Diego : San Diego Arthritis Medical Clinic
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
San Francisco : California Pacific Medical Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
San Francisco : Investigational Site Number 840008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
San Francisco : University of California, San Francisco
Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty
San Francisco : University of California, San Francisco Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
San Leandro : 201
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
San Leandro : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Santa Maria :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Santa Maria : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Santa Maria : Investigational Site Number 840021 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santa Maria : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Santa Maria : 129 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Santa Monica : Orrin M. Troum, MD and Medical Associates
Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects
Santa Monica : Orrin M. Troum, MD and Medical Associates
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Torrance : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Torrance : Novatis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Torrance : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Torrance : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tustin : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tustin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tustin : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Upland :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Upland : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Upland : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Upland : 202
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Upland : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Upland : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Upland : Investigational Site Number 840049 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Upland : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Upland : 164 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Victorville : Site Reference ID/Investigator# 38204
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Victorville : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Walnut Creek : Site Reference ID/Investigator# 40762
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Whittier :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Whittier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Whittier : 172
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Wildomar : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Colorado
Boulder : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Colorado Springs : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Colorado Springs : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Colorado Springs : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Colorado Springs : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Denver :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Denver : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Fort Collins : Orthopedic Center of the Rockies
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Connecticut
Bridgeport : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Stamford : Stamford Therapeutics Consortium
Rheumatoid Arthritis pain?
Trumbull : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Bridgeport :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Bridgeport : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Bridgeport : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Danbury : Site Reference ID/Investigator# 43049
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Danbury : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hamden : 141 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Trumbull : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Trumbull : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Trumbull : New England Research Associates, Llc
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Delaware
Lewes : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lewes : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Lewes : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lewes : 111 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Newark : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Florida
Aventura : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Aventura : South Florida Medical Research
Phase IV, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen.
Aventura : South Florida Medical Research
Study of patients with Osteoarthritis and Rheumatoid Arthritis with a high risk of cardiovascular disease comparing the efficacy and safety of a study medication with other study medications.
Clearwater : Clinical Research of West Florida
Bothered by Arthritis? Concerned About Heart Disease?
Clearwater : Clinical Research of West Florida, Inc.
Volunteers Needed
Debary : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Fort Myers : Clinical Physiology Associates
Collection of Blood Samples
Fort Myers : Clinical Physiology Associates
Rheumatoid Arthritis
Jupitor : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Miami : Pharmax Research Clinic, Inc.
Rheumatoid Arthritis
Rock Island : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
St. Petersburg : Comprehensive Clinical Development, St. Petersburg
Rheumatoid Arthritis
Tampa : Clinical Research of West Florida, Inc.
Bothered by Arthritis? Concerned About Heart Disease?
West Palm Beach : Palm Beach Research Center
Bothered by Arthritis? Concerned about Heart Disease?
West Palm Beach : Metabolic Research Institute, Inc.
We are conducting a clinical research study to test the safety and effectiveness of an investigational medication in patients with rheumatoid arthritis (RA) who were previously unsuccessfully treated with another medication called a tumor necrosis factor-alpha (TNF-a) inhibitor.
View More »
Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Aventura :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Aventura : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Aventura : 142
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Boca Raton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Boca Raton : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Boca Raton : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Brandon : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Brandon : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Coral Springs :
An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)
Daytona Beach : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Daytona Beach : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Daytona Beach : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Debary : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Debary : 151 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Dunedin : Investigational Site Number 840050 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Edgewater : Riverside Clinical Research
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Fort Lauderdale : 190
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Fort Myers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Gainesville : University of Florida
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Jacksonville : Site Reference ID/Investigator# 38687
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Jacksonville : 173
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Jacksonville : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Jacksonville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Jacksonville : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Jacksonville : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Jacksonville : Investigational Site Number 840041 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Jupiter : 196
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Jupiter : Investigational Site Number 840067 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Jupiter : 114 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Largo : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Melbourne :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Miami : Global Clinical Professionals
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Miami :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Miami : Site Reference ID/Investigator# 40105
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Miami : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Miami : 232
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Miami : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Miami : Investigational Site Number 840048 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Naples : 213
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
New Port Richey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
North Miami Beach : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Ocala : 214
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Ocala : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ocala : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Ocala : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Ocala : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Orlando :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Orlando : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Orlando : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Orlando : Investigational Site Number 840006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Orlando : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Ormond Beach : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Ormond Beach : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Palm Harbor :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Palm Harbor : The Arthritis Center
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Palm Harbor : 163
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Palm Harbor : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Palm Harbor : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Palm Harbor : Investigational Site Number 840063 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Pinellas Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Pinellas Park : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Pinellas Park : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Pinellas Park : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Plantation : 166
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Sarasota : Site Reference ID/Investigator# 38083
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Sarasota : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Sarasota : Investigational Site Number 840060 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sarasota : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Sarasota : Sarasota Arthritis Research Center
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
South Miami : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
St Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
St Petersburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
St. Petersburg : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Summerfield : Lakeview Medical Research
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tampa : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tampa : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Tampa : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Tampa : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tampa : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Tampa : 157 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Tampa : 183 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Tampa : Florida Orthopaedic Institute
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Venice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Venice : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Venice : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Vero Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Vero Beach : 200
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Vero Beach : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Zephyr Hills : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Zephyr Hills : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Zephyrhills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Zephyrhills :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Zephyrhills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Georgia
Alpharetta : CSI Research Inc
(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.
Alpharetta : CSI Research Inc
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis
Alpharetta : CSI Research Inc
A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis
Alpharetta : CSI Research Inc
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
Gainesville : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Newnan : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Stockbridge : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Atlanta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Atlanta : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Atlanta : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Atlanta : Investigational Site Number 840003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Atlanta : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Canton : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Canton : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Canton : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Decatur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Decatur : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Decatur : Investigational Site Number 840028 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Duluth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Dunwoody : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Dunwoody : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Gainesville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lawrenceville : Site Reference ID/Investigator# 38688
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Lawrenceville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Macon : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Macon : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Marietta : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Marietta : Investigational Site Number 840027 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Savannah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Stockbridge : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Idaho
Meridian : Advanced Clinical Research, ID
Bothered by Arthritis? Concerned about Heart Disease?
View More »
Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Boise : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Coeur D'alene : 226
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Coeur D'alene : 145
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Idaho Falls :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Idaho Falls : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Idaho Falls : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Idaho Falls : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Idaho Falls : Investigational Site Number 840018 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Idaho Falls : 116 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Meridian : Site Reference ID/Investigator# 38689
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Meridian : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Illinois
Moline : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Springfield : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Chicago : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Chicago : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Chicago : Investigational Site Number 840046 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Decatur : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Glendale : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Glenview : Illinois Bone & Joint Institute, Ltd.
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Maywood : Loyola University Medical Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Moline : 160 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Morton Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Morton Grove : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Quincy : Quincy Medical Group
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Rock Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Rock Island : Site Reference ID/Investigator# 38085
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Rock Island : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rock Island : 219
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rockford : Rockford Orthopedic Associates, Ltd.
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Rockford : Rockford Orthopedics Associates
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Springfield : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Springfield : Site Reference ID/Investigator# 40128
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Springfield : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Springfield : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Springfield : 168 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Indiana
Bloomington : Bloomington Bone and Joint Clinic
Ascension® MCP Post-Approval Study
Brownsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Brownsburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
View More »
Evansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Fort Wayne : Parkview Health
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
South Bend : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
South Bend : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
South Bend : Saint Joseph Regional Medical Center
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Terre Haute : 222
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Iowa
Cedar Rapids : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Bettendorf : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Cedar Rapids :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Cedar Rapids : 215
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Cedar Rapids : 133 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Kansas
Kansas City : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Wichita : Wichita Clinic, PA
Clinical Research Trial studying Rheumatoid Arthritis Therapy and Vaccines
Wichita : Wichita Clinic, PA
Have you been diagnosed with Rheumatoid Arthritis.
Wichita : Wichita Clinic, PA
Have you been diagnosed with Rheumatoid Arthritis?
View More »
Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Kansas City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kansas City : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Kansas City : University of Kansas Medical Center
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Lenexa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Shawnee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Wichita : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Wichita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Wichita : 191
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Wichita : 210
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Witchita : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kentucky
Lexington : University of Kentucky Chandler Medical Center
Have You Been Prescribed a New Medicine for Rheumatoid Arthritis?
Lexington : Kentucky Medical Research Center
Rheumatoid Arthritis
View More »
Bowling Green : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Bowling Green : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bowling Green : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Bowling Green : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Bowling Green : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Bowling Green : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Elizabethtown : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Elizabethtown : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Elizabethtown : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Lexington :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Lexington : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Lexington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lexington : Investigational Site Number 840015 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lexington : Saint Joseph East Hospital
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Lexington : 134
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Louisville : Norton Orthopaedic Specialists
Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty
Owensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Owensboro : Trial Concierge
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Owensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Louisiana
Maryland
Cumberland : The Osteoporosis & Clinical Trials Center
A randomized, double-blind study of the effect of ocrelizumab in combination with methotrexate, compared to methotrexate alone, on the treatment response in methotrexate-naive patients with active rheumatoid arthritis.
Cumberland : The Osteoporosis & Clinical Trials Center
A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate
Towson : Spectrum Clinical Research, Inc.
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)
Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD
A phase 3B, Open-label, Multicenter, Exploratory study to assess changes in Joint Inflammation using ultrasonography in subjects with Rheumatoid Arthritis treated for 12 weeks with Certolizumab Pegol.
Wheaton : The Center for Rheumatology and Bone Research
A 2 arm study to evaluate Tocilizumab IV vs Enbrel SQ for 5 years
Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD
A randomized , double-blind, placebo-controlled , multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of IL-6Ra mAb on top of methotrexate in patients with active rheumatoid arthritis who are inadequate responders of MTX therapy.
Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD
A randomized, double-blind, parallel-group study of Cardiovascular safety in Osteoarthritis or Rheumatoid Arthritis patients with or at high risk for Cardiovascular disease comparing Celecoxib with Naproxen and Ibuprofen.
Wheaton : The Center for Rheumatology and Bone Research
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD
Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis
Wheaton : The Center for Rheumatology and Bone Research - Wheaton, MD
Phase 3b Golimumab Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients who have Inadequate disease control despite treatment with Etanercept (Enbrel) or Adalimumab (Humira)
View More »
Baltimore : Union Memorial Hospital
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Baltimore : 218
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Baltimore : Sinai Hospital of Baltimore
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
Crofton : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Crofton : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Cumberland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Cumberland :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Cumberland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Cumberland : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Cumberland : Investigational Site Number 840073 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Cumberland : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Frederick : Investigational Site Number 840055 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Frederick : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Hagerstown : 177
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Hagerstown : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hagerstown : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Oxon Hill : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Wheaton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Wheaton :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Wheaton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Wheaton : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Wheaton : Investigational Site Number 840013 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Massachusetts
Hyannis : Clinical Research Center of Cape Cod, Inc
Do you have Osteoarthritis or Rheumatoid Arthritis and are at High Risk for Cardiovascular Disease?
View More »
Boston : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Boston : Brigham and Women's Hospital
Patient Rheumatoid Arthritis Social Support Study
Boston : Brigham and Women's Hospital
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Fall River : Site Reference ID/Investigator# 40125
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Fall River : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Haverhill : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hyannis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Newton : Inflexxion, Inc.
Web-based Support to Manage Arthritis Pain
Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Worcester :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Worcester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Worcester : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Worcester : Clinical Pharmacology Study Group
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Worcester : University of Massachusetts Medical School
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
Michigan
Bingham Farms : QUEST Research Institute
Rheumatoid Arthritis Study of an Investigational Therapy for People Taking Methotrexate
View More »
Battle Creek : Pfizer Investigational Site
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Battle Creek :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Battle Creek : 137
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Bingham Farms : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
East Lansing : Mid Michigan Orthopaedic Institute
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Grand Rapids : Orthopaedic Associates of Michigan, PC
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Kalamazoo : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Kalamazoo : 199
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Kalamazoo : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Kalamazoo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lansing : 155
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Petoskey :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
St Clair Shores : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
St. Clair Shores : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Minnesota
Mississippi
Biloxi :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Flowood :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
View More »
Flowood :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Flowood : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Flowood : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Flowood : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Jackson : Arthritis Associates Of Mississippi
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Tupelo :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Missouri
St. Louis : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
St. Louis : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Cape Girardeau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Florissant : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Florissant : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Florissant : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Florissant : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Richmond Heights : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Richmond Heights : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Richmond Heights : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Richmond Heights : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
St Louis :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
St Louis : 134 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
St. Louis : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
St. Louis : 179
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
St. Louis : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
St. Louis : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
St. Louis : Investigational Site Number 840066 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
St. Louis : 112 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Montana
Nebraska
Lincoln : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lincoln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lincoln : 181
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Lincoln : 102 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Omaha : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Omaha : Quality Clinical Research, Inc.
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Omaha : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Omaha : Investigational Site Number 840071 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Omaha : 135
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Nevada
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Las Vegas : Advanced BioMedical Research of America
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Las Vegas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Las Vegas : Desert Orthopaedic Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Las Vegas : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Reno : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
New Hampshire
New Jersey
Freehold : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
New Brunswick : UMDNJ-Robert Wood Johnson Medical School
A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis
New Brunswick : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Tom's River : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Berkeley Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Berkeley Heights : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Clifton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Clifton : Site Reference ID/Investigator# 40124
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Clifton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Egg Harbor Township : Rothman Institute Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Egg Harbor Township : The Rothman Institute Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Freehold : Site Reference ID/Investigator# 38978
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Freehold : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Freehold : 171 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Manalapan :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Newark : University of Medicine & Dentistry of New Jersey
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Toms River : 152 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Voorhees : Site Reference ID/Investigator# 40123
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
New Mexico
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Albuquerque : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Albuquerque : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
View More »
Albuquerque : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Las Cruces : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Las Cruces : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Las Cruces : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
New York
Albany : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Brooklyn : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Lake Success : Biomedical Research Alliance of New York
Rheumatoid Arthritis - Adults
Mineola : Winthrop University Hospital Clinical Trials Center
Rheumatoid Arthritis
New York : The Rockefeller University Hospital
Evaluation of Immune Activation in Rheumatoid Arthritis
Rochester : AAIR Research Center
A Open-Label Study to Evaluate the Safety of Administering Rituxan (Rituximab) at a More Rapid Infusion Rate in Patients with Rheumatoid Arthritis.
Rochester : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Rochester : Rochester Clinical Research
Rheumatoid Arthritis
Rochester : AAIR Research Center
Rheumatoid Arthritis Study
View More »
Albany : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Albany : 154
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Bronx : Site Reference ID/Investigator# 38983
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Brooklyn : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Brooklyn :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Brooklyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Brooklyn : 176
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Brooklyn : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Brooklyn : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Brooklyn : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Brooklyn : 174 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Brooklyn : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Brooklyn : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Brooklyn : 136
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
New Rochelle : Sound Shore Medical Center of Westchester
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
New York :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
New York : Hospital for Special Surgery
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
New York : Investigational Site Number 840056 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
New York City : Kenneth Mroczek, MD-NYU
2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use
Olean : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Olean : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Orchard Park :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Plainview :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Rochester : University of Rochester Medical Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Rochester : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Rochester : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Rochester : Lattimore Orthopaedics P.C.
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
Roslyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Roslyn : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Roslyn : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Roslyn : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Smithtown :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Smithtown : Site Reference ID/Investigator# 38264
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Smithtown : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Smithtown : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Syracuse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Syracuse : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
North Carolina
Cary : PMG Research of Cary
ARTHRITIS AND HEART DISEASE: Research Study
Charlotte : PMG Research of Charlotte
ARTHRITIS AND HEART DISEASE: Research Study
Charlotte : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Hickory : PMG Research of Hickory
ARTHRITIS AND HEART DISEASE: Research Study
Hickory : PMG Research of Hickory
Do you suffer from moderated to severe rheumatoid arthritis?
Hickory : PMG Research of Hickory
Do you take Methotrexate for you Rheumatoid Arthritis?
Hickory : PMG Research of Hickory
Have you been taking Methotrexate for at least 3 months for your Rheumatoid Arthritis?
Raleigh : PMG Research of Raleigh
ARTHRITIS AND HEART DISEASE: Research Study
Salisbury : PMG Research of Salisbury
ARTHRITIS AND HEART DISEASE: Research Study
Salisbury : PMG Research of Salisbury
Do you Have Rheumatoid Arthritis?
Wilmington : PMG Research of Wilmington
ARTHRITIS AND HEART DISEASE: Research Study
Winston-Salem : PMG Research of Winston-Salem
ARTHRITIS AND HEART DISEASE: Research Study
View More »
Asheville : Site Reference ID/Investigator# 38263
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Asheville : Mission Health System
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Belmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Charlotte : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Charlotte :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Charlotte : OrthoCarolina, PA
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Charlotte : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Charlotte : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Charlotte : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Charlotte : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Charlotte : 170 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Charlotte : Box Arthritis And Rheumatology Of The Carolinas, Pllc
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Charlotte : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Durham : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Durham : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Durham : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Durham : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Durham : Michael Bolognesi, MD
INBONE Total Ankle Arthroplasty(TAA)Using Calcaneal Stem Fixation
Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Greensboro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Greensboro : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Greensboro : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Greenville : Site Reference ID/Investigator# 38261
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Hickory : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hickory : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hickory : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Hickory : Investigational Site Number 840068 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Raleigh : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Salisbury : PMG Research of Salisbury
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Sanford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Washington :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Wilmington : Carolina Arthritis Associates
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Winston-salem : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
North Dakota
Ohio
Akron : Radiant Research - Akron
Rheumatoid Arthritis Research Study
Cincinnati : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Cleveland : Rapid Medical Research, Inc. (RMR)
Do you suffer from arthritis pain?
Columbus : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Dayton : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Akron :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Akron : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Cincinnati : 150 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Cincinnati : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Cincinnati : 140
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Cleveland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Cleveland : Cleveland Clinic Orthopaedic
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Columbus :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Columbus : Orthopedic Foot & Ankle Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Dayton : Providence Health Partners
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Dayton :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Dayton : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Dayton : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Dayton : 100 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Gallipolis : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kettering : Kettering Health Network
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Mayfield Village : Site Reference ID/Investigator# 39024
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Mayfield Village : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Mayfield Village : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Middleburg Heights : Paramount Medical Research & Consulting, LLC
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Middleburg Heights :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Middleburg Heights : Paramount Medical Research & Consulting, Llc
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Perrysburg : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Perrysburg : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Perrysburg : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Perrysburg : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Toledo : Zalicus Investigational Site
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
Toledo : Investigational Site Number 840044 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Oklahoma
Oklahoma City : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Oklahoma City : Bone and Joint Hospital at St. Anthony
Rheumatoid Arthritis Research Study
Oklahoma City : Bone and Joint Hospital at St. Anthony
Rheumatoid Arthritis
The Flex-V Study
View More »
Norman :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Oklahoma City :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Oklahoma City : Site Reference ID/Investigator# 40127
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Oklahoma City : Health Research Institute, Inc.
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Oklahoma City : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Oklahoma City : Investigational Site Number 840002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Oklahoma City : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Oklahoma City : 110 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Oklahoma City : Health Research Of Oklahoma
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tulsa : Investigational Site Number 840011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tulsa : Investigational Site Number 840065 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Oregon
Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bend : Site Reference ID/Investigator# 38202
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Bend : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bend : The Center
Ascension® MCP Post-Approval Study
Eugene : Site Reference ID/Investigator# 39023
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
View More »
Lake Oswego : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Lake Oswego : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lake Oswego : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Portland : Novatis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Portland : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Salem : Willamette Orthopedic Group LLC
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
Pennsylvania
Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bethlehem : Investigational Site Number 840010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bethlehem : East Penn Rheumatology Associates, P.C.
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
View More »
Ducansville : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Duncansville : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Duncansville : Pfizer Investigational Site
A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Duncansville :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Duncansville : Site Reference ID/Investigator# 38265
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Duncansville : Research Site
Effects of Denosumab on the Pharmacokinetics of Etanercept
Duncansville : 167
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Duncansville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Duncansville : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Duncansville : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Duncansville : Investigational Site Number 840009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Duncansville : 165 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Duncansville : Altoona Center For Clinical Research
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Duncansville : Altoona Center For Clinical Research
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Duncansville : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Duncansville : 132
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Erie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Erie : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Limerick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Philadelphia : University of Pennsylvania Health Systems-PA Foot and Ankle Surgeons
2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Philadelphia :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Philadelphia : The Rothman Institute
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Philadelphia : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Philadelphia : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Philadelphia : Rothman Institute Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Philadelphia : The Rothman Institute Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Phoenixville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Pittsburgh : University of Pittsburgh - Oakland Falk Clinic
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Pottstown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Reading : Investigational Site Number 840062 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Souderton :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Waxford : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Waxford : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Waxford : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
West Reading :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
West Reading : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
West Reading : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Wexford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Wexford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Willow Grove :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Willow Grove : 220
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Wynnewood :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Wyomissing : 168
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Rhode Island
South Carolina
Greer : Radiant Research - Greer
Rheumatoid Arthritis Research
Mt Pleasant : PMG Research of Charleston
ARTHRITIS AND HEART DISEASE: Research Study
Rock Hill : Carolinas Research Associates
Bothered by Arthritis? Concerned About Heart Disease?
View More »
Charleston :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Charleston : 189
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Charleston : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Charleston : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Charleston : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Columbia : Investigational Site Number 840058 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Greenville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Greenville : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Greenville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Greenville : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Greer : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Greer : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
North Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
North Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
North Charleston : Investigational Site Number 840016 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Orangeburg : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Simpsonville : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Taylors : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
South Dakota
Tennessee
Bristol : PMG Research of Bristol
ARTHRITIS AND HEART DISEASE: Research Study
Nashville : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Hendersonville : 204
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Hixson : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hixson : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Jackson : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Jackson :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Jackson :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Jackson : Site Reference ID/Investigator# 38082
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Jackson : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Jackson : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Jackson : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Jackson : Investigational Site Number 840025 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Jackson : 133
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Johnson City : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Knoxville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Knoxville : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Knoxville : 160
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Memphis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Memphis : Campbell Clinic / InMotion Orthopaedic Research Center
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Memphis : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Memphis : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Memphis : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Memphis : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nashville : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Nashville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Nashville : 105 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Texas
Amarillo : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Austin : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Dallas : Metroplex Clinical Research Center
A Multicenter, Randomized, Double-Period, Double-Blind Study to Determine the Optimal Protocol for Treatment Initiation with Methotrexate and Adalimumab Combination Therapy in Patients with Early Rheumatoid Arthritis
Dallas : Metroplex Clinical Research Center
A randomized, double-blind, parallel group, international study to evaluate the safety and efficacy of ocrelizumab compared to placebo in patients with active rheumatoid arthritis who have an inadequate response to at least one anti-TNF therapy.
Dallas : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Houston : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Houston : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Houston : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Houston : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Houston : DynaMed Clinical Research
Osteoarthritis or Rheumatoid Arthritis - Houston, TX
Houston : DM Clinical Research
Rheumatoid Arthritis
Mesquite : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
Nassau Bay : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
San Antonio : Sun Research Institute
Are you taking Humira or Cimzia? Have you taken these medications within the past 90 days?
San Antonio : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
San Antonio : Sun Research Institute
Rheumatoid Arthritis in people taking Methotrexate
San Antonio : Sun Research Institute
Rheumatoid Arthritis with poor response to Methotrexate?
Victoria : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Allen : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Amarillo : 185
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Amarillo : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Amarillo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Austin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Austin : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Austin : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Austin : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Austin : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Austin : 135 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Carrollton :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Corpus Christi :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Corpus Christi : 178
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Corpus Christi : 151
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Dallas : Charles E. Cook, MD
2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Dallas : Site Reference ID/Investigator# 37980
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Dallas : Site Reference ID/Investigator# 44888
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Dallas : Texas Health Research & Education Institute
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Dallas : Research Site
Effects of Denosumab on the Pharmacokinetics of Etanercept
Dallas : 162
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Dallas : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Dallas : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Dallas : Investigational Site Number 840001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Dallas : Investigational Site Number 840022 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Dallas : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Dallas : 128 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Dallas : 131
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Dallas : 146
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Houston : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Houston : Site Reference ID/Investigator# 43050
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Houston : Fondren Orthopedic Group
Ascension® MCP Post-Approval Study
Houston : St. Luke's Episcopal Hospital
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Houston : 206
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Houston : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Houston : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Houston : Investigational Site Number 840020 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Houston : 132 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Houston : 138 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Houston : 126 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Houston : 181 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Houston : Memorial Bone and Joint Clinic
Post PMA-Approval Study: New Enrollment Post PMA-Approval Study Post-approval Study Group (New Enrollment)
Houston : Texas Orthopedic Hospital
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Lake Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lake Jackson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lubbock : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lubbock : Investigational Site Number 840069 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lubbock : Research Site
Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis
Mesquite : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Mesquite :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Mesquite :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Mesquite : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mesquite : 158
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Mesquite : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Mesquite : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Mesquite : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mesquite : Investigational Site Number 840074 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Mesquite : 145 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Nassau Bay :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nassau Bay : 175
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Nassau Bay : 143 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
North Richard Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
North Richland Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
North Richland Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Plano : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
San Antonio : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
San Antonio : Novartis Investigative Site
A Biomarker Study of Secukinumab in Rheumatoid Arthritis Patients
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
San Antonio : Site Reference ID/Investigator# 43735
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
San Antonio : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
San Antonio : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Antonio : 197
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
San Antonio : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
San Antonio : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
San Antonio : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
San Antonio : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
San Antonio : 122 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
San Antonio : 139
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Sugar Land :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Sugarland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Victoria : 142 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Victoria : 165
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Waco : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Utah
West Jordan : Advanced Clinical Research, UT
There's a new clinical study for people who have arthritis and are also at risk for heart disease.
View More »
Salt Lake City : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Vermont
Virginia
Arlington :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Chesapeake : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Chesapeake : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
View More »
Chesapeake : 139 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Richmond : Site Reference ID/Investigator# 44344
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Richmond : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Williamsburg : The Center for Excellence in Aging and Geriatric Health
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Washington
Seattle : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Kennewick : Apex Clinical Research
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Olympia : South Puget Sound Clinical Research Center
A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients With a 12 Week Open-label Extension
Seattle : Site Reference ID/Investigator# 38542
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Seattle : Site Reference ID/Investigator# 40210
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Seattle : Site Reference ID/Investigator# 38084
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Seattle :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Seattle : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Seattle : Seattle Rheumatology Associates
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Seattle : University of Washington Medical Center
Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Spokane :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Spokane : Site Reference ID/Investigator# 38424
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Spokane : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Spokane : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Spokane : 157
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tacoma :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Tacoma : Site Reference ID/Investigator# 38203
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tacoma : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Tacoma : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tacoma : Investigational Site Number 840061 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tacoma : 175 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
West Virginia
Clarksburg : Center Location:
Can you Count 6 or More Tender and Swollen Joints Plus Take Methotrexate?
View More »
Beckley : 136 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Clarksburg : Vertex Investigational Site Updated
24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate
Clarksburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Clarksburg :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Clarksburg : Investigational Site
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
Clarksburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Clarksburg : 183
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Clarksburg : 167 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Wisconsin
Franklin : Site Reference ID/Investigator# 38087
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Glendale :
A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)
Glendale : 174
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
La Crosse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Milwaukee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
View More »
Milwaukee : Medical College of Wisconsin
Ankle Joint Replacement Outcomes Study
Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Argentina
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Buenos Aires : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
View More »
Buenos Aires : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Buenos Aires : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Buenos Aires : Investigational Site Number 032005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Buenos Aires : Investigational Site Number 032007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Buenos Aires : Investigational Site Number 032008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Buenos Aires : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Caba : Investigational Site Number 032006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Capital Federal : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Ciudad Autonoma Bs As : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ciudad Autonoma Bs As : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Cordoba : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Cordoba : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Cordoba : Investigational Site Number 032002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Cordoba : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Córdoba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Córdoba : Investigational Site Number 032003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Lujan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mar Del Plata : Investigational Site Number 032012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Mendoza :
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Quilmes :
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Quilmes : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Quilmes : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Quilmes : Investigational Site Number 032011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Ramos Mejia : Investigational Site Number 032010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rosario : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Rosario : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Rosario : Investigational Site Number 032001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Rosario : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
San Isidro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
San Isidro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Juan : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
San Juan : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
San Juan : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
San Miguel de Tucuman : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
San Miguel de Tucuman : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
San Miguel De Tucuman : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tucuman : Investigational Site Number 032004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tucuman : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Zarate : Investigational Site Number 032009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Australia
Adelaide :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Cairns : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Cairns : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Campbelltown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Campbelltown : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Camperdown : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Camperdown : Investigational Site Number 036003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Clayton : Investigational Site Number 036005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Coffs Harbour : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Dulwich : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Fitzroy : Investigational Site Number 036012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Garran : Investigational Site Number 036010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Heidelberg : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Heidelberg West : Investigational Site Number 036004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Herston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Herston : Investigational Site Number 036009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Hobart :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Malvern : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Malvern East : Site Reference ID/Investigator# 63354
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Maroochydore : Site Reference ID/Investigator# 63355
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
Maroochydore : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Maroochydore : Investigational Site Number 036001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Shenton Park : Site Reference ID/Investigator# 63353
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
Southport : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
St Leonards : Investigational Site Number 036006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sydney : Investigational Site Number 036011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Victoria Park : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Woodville :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Woodville : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Woodville : Investigational Site Number 036007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Austria
Graz : Investigational Site Number 040001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Innsbruck :
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Vienna : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Wien :
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate
Wien : 50
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
View More »
Wien : Investigational Site Number 040002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Belarus
Belarus Site Information : Merck Sharp & Dohme IDEA, Inc.
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)
Belgium
Aalst : Site Reference ID/Investigator# 4791
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Aalst : Site Reference ID/Investigator# 4811
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Aalst : Site Reference ID/Investigator# 4821
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Amel : Site Reference ID/Investigator# 28430
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Antwerp : Site Reference ID/Investigator# 4817
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
View More »
Antwerp : Site Reference ID/Investigator# 4830
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Arlon : Site Reference ID/Investigator# 4834
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Assebroek : Site Reference ID/Investigator# 4837
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Assebroek : Site Reference ID/Investigator# 4848
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ath : Site Reference ID/Investigator# 28454
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Audregnies : Site Reference ID/Investigator# 4773
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Baudour : Site Reference ID/Investigator# 4856
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Belsele : Site Reference ID/Investigator# 4810
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Bornem : Site Reference ID/Investigator# 28445
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Bruges : Site Reference ID/Investigator# 4842
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brugge : Algemeen Ziekenhuis Sint Jan
Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)
Brussels : Site Reference ID/Investigator# 28448
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28449
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4766
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4770
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Ref # / Investigator 4815
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Ref # / Investigator 62674
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28439
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4863
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 4797
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28420
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : Site Reference ID/Investigator# 28405
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Brussels : 51
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Brussels : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Brussels : 401 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Bruxelles :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Bruxelles : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Bruxelles : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Champion : Site Ref # / Investigator 57023
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Charleroi : Site Reference ID/Investigator# 28408
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Charleroi : Site Reference ID/Investigator# 28462
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Courcelles : Site Reference ID/Investigator# 28415
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Destelbergen : Site Reference ID/Investigator# 28433
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Dinant : Site Reference ID/Investigator# 4772
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Edegem :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Edegem : Site Reference ID/Investigator# 4847
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Eeklo : Site Reference ID/Investigator# 28421
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Flemalle : Site Reference ID/Investigator# 4798
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Forchies-la-Marche : Site Reference ID/Investigator# 4831
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Genk : Site Reference ID/Investigator# 4852
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 28452
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4855
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4803
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 28465
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4781
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Site Reference ID/Investigator# 4792
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Genk : Investigational Site Number 056003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Gent : Site Reference ID/Investigator# 28429
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gent : 31
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Gent : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Gent : Universitair Ziekenhuis
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
Gentbrugge : Site Reference ID/Investigator# 28424
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4857
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4827
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4778
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4807
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4822
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 4864
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Ghent : Site Reference ID/Investigator# 63360
Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab.
Gilly :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Gilly : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Gistel : Site Reference ID/Investigator# 4838
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gistel : Site Ref # / Investigator 56987
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Godinne :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Gosselies : Site Reference ID/Investigator# 4763
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Gosselies : Site Reference ID/Investigator# 4799
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Halle : Site Reference ID/Investigator# 28441
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hamme : Site Reference ID/Investigator# 4819
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hasselt : Site Reference ID/Investigator# 4775
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hasselt : Site Reference ID/Investigator# 4777
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Hasselt : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Heusy :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Hoboken : Site Reference ID/Investigator# 28428
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kalmthout : Site Reference ID/Investigator# 4836
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Keerbergen : Site Reference ID/Investigator# 4796
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 4780
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 28453
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Site Reference ID/Investigator# 28463
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Kortrijk : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Kortrijk : 36
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
La Louviere : Site Reference ID/Investigator# 4764
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 28418
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 4768
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
La Louviere : Site Reference ID/Investigator# 4786
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lennik : Site Reference ID/Investigator# 4805
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Leuven : Site Reference ID/Investigator# 4814
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Leuven : Site Reference ID/Investigator# 4865
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Leuze-en-Hainaut : Site Reference ID/Investigator# 4809
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Libramont-Chevigny : Site Reference ID/Investigator# 4849
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Liege : Site Reference ID/Investigator# 28425
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28407
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 4841
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28419
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Site Reference ID/Investigator# 28451
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Liege : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Liege : 400 Updated
Open-label Study to Assess the Safety and Efficacy of CDP6038 in Patients Who Completed RA0056
Liège : Investigational Site Number 056001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lier : Site Reference ID/Investigator# 4782
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lobbes : Site Reference ID/Investigator# 4795
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lokeren : Site Reference ID/Investigator# 4779
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Lommel : Site Reference ID/Investigator# 4808
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Maarkedaal : Site Reference ID/Investigator# 4789
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Malle : Site Reference ID/Investigator# 4839
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Marchienne-au-Pont : Site Reference ID/Investigator# 28436
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mechelen : Site Reference ID/Investigator# 4801
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mechelen : Site Reference ID/Investigator# 4844
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merelbeke : Site Reference ID/Investigator# 4816
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merksem : Site Reference ID/Investigator# 4806
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Merksem : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Mons : Site Reference ID/Investigator# 4804
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mons : Site Reference ID/Investigator# 4840
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Mons : Site Reference ID/Investigator# 28440
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Montegnee : Site Reference ID/Investigator# 4820
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Montignies-sur-Sambre : Site Reference ID/Investigator# 4812
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Namur : Site Reference ID/Investigator# 4818
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Namur : Site Reference ID/Investigator# 4788
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Nazareth : Site Reference ID/Investigator# 4861
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Neupre : Site Reference ID/Investigator# 4765
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Oostende :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Oostende : Site Reference ID/Investigator# 28432
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Oudenaarde : Site Ref # / Investigator 56991
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Plainevaux : Site Reference ID/Investigator# 4794
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Profondeville : Site Reference ID/Investigator# 4850
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Putte : Site Reference ID/Investigator# 28464
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Roeselare : Site Reference ID/Investigator# 28442
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Roeselare : Site Ref # / Investigator 28443
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sijsele : Site Reference ID/Investigator# 46462
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sijsele : Site Reference ID/Investigator# 4833
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Sint-Niklaas : Site Reference ID/Investigator# 4784
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Tielt : Site Reference ID/Investigator# 28446
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Turnhout : Site Reference ID/Investigator# 28447
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Veldegem : Site Reference ID/Investigator# 4774
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Verviers : Site Reference ID/Investigator# 28437
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Verviers : Site Reference ID/Investigator# 4851
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Waremme : Site Reference ID/Investigator# 28427
Belgian Registry of HUMIRA (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Wilrijk :
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)
Yvoir : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Yvoir : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Bosnia and Herzegovina
Banja Luka :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)
Mostar : Sveučilišna klinička bolnica Mostar
Long Term Extension Study For SPM-005 Participants
Mostar : Sveučilišna klinička bolnica Mostar
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis
Sarajevo : Klinicki Centar Univerziteta, Reumatologija
Long Term Extension Study For SPM-005 Participants
Sarajevo : Klinicki Centar Univerziteta, Reumatologija
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis
Brazil
Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Campinas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Campinas : Investigational Site Number 076008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Campinas : Investigational Site Number 076012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
View More »
Caxias Do Sul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Caxias Do Sul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Curitiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Curitiba : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Curitiba : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Curitiba : Investigational Site Number 076001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Fortaleza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Fortaleza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Goiania :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Goiania : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Goiania : Investigational Site Number 076006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Juiz De Fora : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Juiz De Fora : Investigational Site Number 076010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Porto Alegre : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Porto Alegre : Investigational Site Number 076004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Recife : Investigational Site Number 076007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Rio De Janeiro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rio De Janeiro : Investigational Site Number 076005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Salvador : Investigational Site Number 076011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sao Paulo : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Sao Paulo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Sao Paulo : Investigational Site Number 076002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sao Paulo : Investigational Site Number 076003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Setor Oeste/Goiania : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Vitoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Vitoria : Investigational Site Number 076013 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bulgaria
Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Burgas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Pleven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Pleven : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
View More »
Pleven : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Pleven : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Plovdiv : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Plovdiv : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Plovdiv : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Plovdiv : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Rousse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Ruse : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sevlievo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Sevlievo : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Sevlievo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sofia : Nycomed Investigational Site
A Trial to Evaluate the Safety and Tolerability of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis
Sofia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Sofia : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Sofia : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Sofia : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Varna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Varna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Veliko Tarnovo : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Veliko Tarnovo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Canada
Bowmanville : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Bowmanville : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Bowmanville : Site Ref # / Investigator 47667
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Brampton :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Brampton : Site Reference ID/Investigator# 37506
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
View More »
Brampton : Site Reference ID/Investigator# 38057
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Brampton : Site Reference ID/Investigator# 37515
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Burlington :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Burlington : Investigational Site Number 124004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Burlington : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Burnaby : Site Ref # / Investigator 52149
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Calgary : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Calgary : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Calgary : Site Reference ID/Investigator# 37514
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Calgary : Site Reference ID/Investigator# 37504
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Calgary : Site Reference ID/Investigator# 37521
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Cranbrook : Site Reference ID/Investigator# 52154
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Downsview : Site Ref # / Investigator 58484
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Edmonton : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Edmonton : Site Reference ID/Investigator# 37536
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Edmonton : Site Reference ID/Investigator# 37505
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Edmonton : Site Reference ID/Investigator# 37520
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Edmonton : Site Reference ID/Investigator# 37535
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Edmonton : Site Ref # / Investigator 37541
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Fredericton : Site Reference ID/Investigator# 37503
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Fredericton : Site Reference ID/Investigator# 37525
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Guelph : Site Reference ID/Investigator# 38063
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Halifax : Queen Elizabeth II Health Services
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Hamilton : Site Reference ID/Investigator# 67105
A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab
Hamilton :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Hamilton : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hamilton : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hamilton : Site Ref # / Investigator 55124
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Hamilton : Site Reference ID/Investigator# 47662
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Hamilton : Site Reference ID/Investigator# 38060
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Hamilton : Site Reference ID/Investigator# 38068
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Kamloops : Site Reference ID/Investigator# 38062
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Kamloops : Site Ref # / Investigator 54102
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Kamloops : Isis Investigational site
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
Kelowna : Site Reference ID/Investigator# 52152
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Kitchener :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Kitchener :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Kitchener : Site Reference ID/Investigator# 37526
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Kitchener : Site Ref # / Investigator 55123
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Laval : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Laval : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Laval : Site Reference ID/Investigator# 47674
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Lethbridge : Site Reference ID/Investigator# 37516
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Levis : Site Reference ID/Investigator# 64043
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
London :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Lunenburg : Site Reference ID/Investigator# 47670
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Mississauga :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Mississauga : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Mississauga : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mississauga : Investigational Site Number 124003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Mississauga : Site Reference ID/Investigator# 37510
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Mississauga : Site Reference ID/Investigator# 37522
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Mississauga - Chow : Location n°31 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Montreal :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Montreal :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Montreal : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Montreal : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Montreal : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Montreal : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Montreal : Site Reference ID/Investigator# 37527
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 37539
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 47663
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 60122
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 37502
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 37537
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Site Reference ID/Investigator# 37532
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Montreal : Isis Investigational Site
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
Nanaimo : Site Reference ID/Investigator# 38069
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Nepean : Site Reference ID/Investigator# 37513
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Newmarket :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Newmarket : Investigational Site Number 124008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Newmarket : Site Reference ID/Investigator# 37542
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
North Vancouver : Site Reference ID/Investigator# 52148
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
North York : Site Ref # / Investigator 54103
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Ontario : Location n°36 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Ottawa : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Ottawa : Site Reference ID/Investigator# 37524
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Ottawa : Site Reference ID/Investigator# 38070
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Ottawa : Site Reference ID/Investigator# 37507
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Outremont : Site Reference ID/Investigator# 37523
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Penticton : Site Reference ID/Investigator# 38066
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Penticton : Site Reference ID/Investigator# 37538
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Peterborough : Site Reference ID/Investigator# 37529
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Prince George : Site Reference ID/Investigator# 47672
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Quebec : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Quebec : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Quebec City :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Quispamsis :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Rimouski :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Rimouski :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Rimouski : Site Reference ID/Investigator# 47664
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Rimouski : Location n°34 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Sainte-foy :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Saint-Eustache : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Saskatchewan : Location n°33 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Saskatoon :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Scarborough : Site Reference ID/Investigator# 37518
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Sherbrooke : Site Reference ID/Investigator# 38059
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Sherbrooke : Site Ref # / Investigator 47676
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
St John's :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
St John's : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
St John's : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
St. Catharines :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
St. Catharines :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
St. Catharines : Investigational Site Number 124002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
St. Catharines : Site Reference ID/Investigator# 37534
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
St. Eustache : Site Reference ID/Investigator# 37528
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
St. John's : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
St. John's : Site Reference ID/Investigator# 37533
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
St. John's : Site Reference ID/Investigator# 37511
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
St. John's : Site Reference ID/Investigator# 37530
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Toronto : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Toronto : Investigational Site Number 124005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Toronto : Investigational Site Number 124001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Toronto : Site Reference ID/Investigator# 37508
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 38058
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 38065
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 37509
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 35722
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 47668
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Site Reference ID/Investigator# 47678
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Toronto : Isis Investigational Site
Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis
Toronto : Location n°35 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Trois-rivieres : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Trois-Rivieres : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Trois-Rivieres : Site Reference ID/Investigator# 47665
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Vancouver :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Vancouver : St. Paul's Hospital
Augment™ Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions
Vancouver : University of British Columbia Hospital, Vancouver
Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty
Vancouver : University of British Columbia Hospital, Vancouver Updated
Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty
Vancouver : Site Ref # / Investigator 52151
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Vancouver : Site Reference ID/Investigator# 37540
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Vancouver : Site Reference ID/Investigator# 43122
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Victoria : Site Reference ID/Investigator# 37517
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Victoria : Site Reference ID/Investigator# 37519
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Windsor :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Windsor : Site Reference ID/Investigator# 52147
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Winnipeg :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Winnipeg :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Winnipeg : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Winnipeg : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Winnipeg : Investigational Site Number 124012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Winnipeg : Research Site
Moderate Rheumatoid Arthritis (RA) With Enbrel
Winnipeg : Site Reference ID/Investigator# 37512
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Winnipeg : Site Reference ID/Investigator# 54105
Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA
Chile
Osorno : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Osorno : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Osorno : Investigational Site Number 152005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Puerto Montt : Investigational Site Number 152010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
View More »
Santiago : Investigational Site Number 152011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152013 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Santiago : Investigational Site Number 152002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Valdivia : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Valdivia : Investigational Site Number 152004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Vina Del Mar : Investigational Site Number 152006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Viña Del Mar : Investigational Site Number 152007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
China
Baotou : The First Affiliated Hospital of Baotou Medical College
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Baotou city : Baotou Central Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Changsha : The Second Xiangya Hospital of Central South University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Chengdu : Si Chuan Huaxi Hospital/Rheumatology Department
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Chongqing : Daping Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
View More »
Fuzhou : Fujian Provincial Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Guangzhou : The First Affiliated Hospital of Guangzhou University of Chinese Medicine
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Haerbin : No. 199
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Lanzhou : Lanzhou University Second Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Nanjing : Jiangsu Province Hospital/Department of Rheumatology
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Nantong : Affiliated Hospital of Nantong University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Taiyuan : The Second Hospital of Shanxi Medical University
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Urumqi : Xinjiang Uygur Autonomous Region People's Hospital
A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department
Colombia
Barranquilla :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Barranquilla : Investigational Site Number 170004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
View More »
Bogota :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Bogota : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bogota : Investigational Site Number 170001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bogota : Investigational Site Number 170008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bogota : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Bogotá : Investigational Site Number 170006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bucaramanga : Investigational Site Number 170007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bucaramanga : Investigational Site Number 170009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Chía : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Medellin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Medellin : Investigational Site Number 170002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Medellin : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Croatia
Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Opatija : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Osijek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Osijek : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Rijeka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Split : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Split : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Zagreb : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Zagreb : Sisters of Mercy Clinical Hospital Centre
Long Term Extension Study For SPM-005 Participants
Zagreb : Sisters of Mercy Clinical Hospital Centre
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis
Czech Republic
Brno : 108
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Brno : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Brno : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Brno : Site Ref # / Investigator 55810
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Bruntal : Novartis Investigative site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents
View More »
Bruntal : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Bruntal : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Bruntal : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Ceske Budejovice : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ceske Budejovice : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Chomutov : Site Ref # / Investigator 55807
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Hlucin : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hlucin : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Hlucin : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hostivice : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Jihlava : Site Ref # / Investigator 55815
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Liberec : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Liberec : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Ostrava : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Ostrava : Novartis Investigational site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents
Ostrava : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Ostrava : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Ostrava - Trebovice : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Ostrava-trebovice : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Pardubice : Site Ref # / Investigator 55816
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Prague : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Praha : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Praha : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Praha : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Praha 1 : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Praha 11 - Chodov : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Praha 2 : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Praha 4 : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Sokolov : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Terezin : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Uherske Hradiste : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Uherske Hradiste : Novartis Investigational site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents
Uherske Hradiste : Site Ref # / Investigator 55814
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Uherské Hradiste : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Zlin : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Zlin : Novartis Investigative site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents
Zlin : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Zlin : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Zlin : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Zlin : Site Ref # / Investigator 55806
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Zlín : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Denmark
Ålborg :
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Frederiksberg :
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Frederiksberg : 003
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Hellerup : 002
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Hjorring : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
View More »
Holbæk :
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Hvidovre : 001
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Odense :
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Slagelse : 016
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Svendborg :
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment
Estonia
Parnu : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tallinn : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Tallinn : Investigational Site Number 233001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tallinn : Investigational Site Number 233002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tartu : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Finland
Hämeenlinna :
An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)
Helsinki :
An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)
Helsinki : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Helsinki : Investigational Site Number 246001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Helsinki : Helsinki University Central Hopsital
REstore Working Ability in RheumatoiD Arthritis
View More »
Hyvinkää :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Hyvinkää : Investigational Site Number 246002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Paimio :
An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)
Pori : Investigational Site Number 246003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Riihimäki :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis
Rovaniemi : Lappland Central Hospital
REstore Working Ability in RheumatoiD Arthritis
Tampere :
An Observational Study on Patients With Rheumatoid Arthritis Trated With MabThera (Rituximab)
Tampere : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Tampere : Tampere University hospital, Rheumatology Centre
REstore Working Ability in RheumatoiD Arthritis
Turku : The Turku Universitry Central Hopsital
REstore Working Ability in RheumatoiD Arthritis
France
Amiens :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Amiens : Location n°41 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Amiens Cedex : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Angers :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Annecy : Clinique Generale D'Annecy
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
View More »
Bobigny : Location n°13 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Bordeaux Cedex : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Carcassonne :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Chambray Les Tours : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Chambray Les Tours : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Creteil :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Dreux : Location n°39 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Evian Les Bains :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Frejus :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Grenoble : Location n°14 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Libourne :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Lille :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Lomme :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Marseille : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Meaux : Location n°40 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Metz : Hospital Belle Isle
An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
Metz Tessy :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Montpellier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Montpellier : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Montpellier Cedex 5 : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Nantes Cedex 1 : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Nevers :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Nice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Orleans : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Orleans Cedex 1 : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Paris :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Paris : Location n°25 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Paris (Hop Bichat) : Location n°37 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Paris Cedex 12 : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Paris Cedex 13 : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Paris Cedex 14 : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Perigueux :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Pierre Benite :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Poitiers : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Pontoise :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Reims : CHRU Reims Hôpital Maison Blanche
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
Saint-Etienne Cedex 02 : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Saint-priest En Jarez :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
St Brieuc :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
St Herblain : Polyclinique de l'Atlantique
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
St Nazaire :
Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab)
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Strasbourg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Strasbourg : Location n°38 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Strasbourg Cedex : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Thionville :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Toulouse : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Villeneuve St Georges :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Germany
Aachen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Aachen :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Aachen : Site Reference ID/Investigator# 35036
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Aachen : Site Reference ID/Investigator# 35033
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Aachen : Site Reference ID/Investigator# 35034
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
View More »
Aachen : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Aachen : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Achern : Site Reference ID/Investigator# 53919
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ahlen : Site Reference ID/Investigator# 35510
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ahlen : Site Reference ID/Investigator# 30699
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ahrensburg : Site Reference ID/Investigator# 35040
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ahrensburg : Site Reference ID/Investigator# 30726
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Aichhalden : Site Reference ID/Investigator# 53883
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Altenburg : Site Reference ID/Investigator# 35043
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Altenburg : Site Reference ID/Investigator# 35041
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Altenburg : Site Reference ID/Investigator# 30727
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Altenholz : Site Reference ID/Investigator# 35046
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Altenholz : Site Reference ID/Investigator# 51043
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Amberg : Site Reference ID/Investigator# 35049
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Amberg : Site Reference ID/Investigator# 53974
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Amberg : Site Reference ID/Investigator# 35050
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Amberg : Site Reference ID/Investigator# 30398
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Arnstadt : Site Reference ID/Investigator# 35057
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Arnstadt : Site Ref # / Investigator 53603
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Attendorn : Site Reference ID/Investigator# 35520
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Auerbach : Site Reference ID/Investigator# 30006
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Augsburg : Site Reference ID/Investigator# 33349
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Augsburg : Site Reference ID/Investigator# 33347
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Augsburg : Site Reference ID/Investigator# 30717
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Abbach : Site Reference ID/Investigator# 33358
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Abbach : Site Reference ID/Investigator# 33361
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Abbach : Site Reference ID/Investigator# 33359
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Abbach : Site Reference ID/Investigator# 33356
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Abbach : Site Reference ID/Investigator# 30714
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Aibling :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Bad Aibling : Site Reference ID/Investigator# 35142
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Aibling : Site Reference ID/Investigator# 33362
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Aibling : Site Reference ID/Investigator# 35084
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Aibling : Site Reference ID/Investigator# 53968
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Bellingen : Site Reference ID/Investigator# 53966
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Bentheim : Site Reference ID/Investigator# 35523
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Brambach : Site Reference ID/Investigator# 35570
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Bramstedt :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Bad Bramstedt : Site Reference ID/Investigator# 35573
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Bramstedt : Site Reference ID/Investigator# 53903
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Bramstedt : Site Reference ID/Investigator# 35571
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Bramstedt : Site Reference ID/Investigator# 49288
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Buchau : Site Reference ID/Investigator# 53929
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Doberan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Bad Doberan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bad Doberan : Site Ref # / Investigator 53610
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Endbach : Site Reference ID/Investigator# 33372
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Endbach : Site Reference ID/Investigator# 33369
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Endbach : Site Reference ID/Investigator# 33370
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Homburg : Site Ref # / Investigator 51066
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Iburg : Site Reference ID/Investigator# 33378
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Iburg : Site Reference ID/Investigator# 33382
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Iburg : Site Reference ID/Investigator# 33380
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Iburg : Site Reference ID/Investigator# 30422
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Iburg : Site Reference ID/Investigator# 30372
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Kissingen : Site Reference ID/Investigator# 33384
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Kreuznach : Site Reference ID/Investigator# 35575
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Kreuznach : Site Reference ID/Investigator# 33387
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Kreuznach : Site Reference ID/Investigator# 33385
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Kreuznach : Site Reference ID/Investigator# 30348
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Liebenwerda : Site Reference ID/Investigator# 33389
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Liebenwerda : Site Reference ID/Investigator# 30705
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Liebenwerda 04924 : Site Reference ID/Investigator# 33391
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Mergentheim : Site Reference ID/Investigator# 53942
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Muender : Site Reference ID/Investigator# 33396
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Muender : Site Reference ID/Investigator# 33394
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Nauheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Bad Nauheim :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Bad Nauheim : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bad Nauheim : Site Ref # / Investigator 33398
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Nauheim : Investigational Site Number 276011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bad Nauheim : Site Ref # / Investigator 51073
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Neuenahr : Site Reference ID/Investigator# 35578
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Neuenahr : Site Reference ID/Investigator# 33399
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Neuenahr : Site Reference ID/Investigator# 35576
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Neuenahr : Site Ref # / Investigator 53611
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Neuenahr : Site Ref # / Investigator 53384
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Pyrmont : Site Reference ID/Investigator# 53980
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Rappenau : Site Reference ID/Investigator# 33404
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Rappenau : Site Reference ID/Investigator# 33402
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Salzungen : Site Reference ID/Investigator# 51883
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Soden-Salmuenster : Site Reference ID/Investigator# 33412
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bad Soden-Salmuenster : Site Reference ID/Investigator# 33410
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Staffelstein :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Bad Staffelstein : Site Reference ID/Investigator# 33415
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Staffelstein : Site Reference ID/Investigator# 30334
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Toelz : Site Reference ID/Investigator# 54804
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bad Toelz : Site Reference ID/Investigator# 49263
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bad Toelz : Site Reference ID/Investigator# 49261
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Baden-Baden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Baden-Baden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Baden-Baden : Site Reference ID/Investigator# 33425
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Baden-Baden : Site Reference ID/Investigator# 33423
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Baden-Baden : Site Reference ID/Investigator# 30725
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bamberg : Site Reference ID/Investigator# 33429
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bamberg : Site Reference ID/Investigator# 33427
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bamberg : Site Reference ID/Investigator# 30324
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bautzen : Site Reference ID/Investigator# 33438
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bautzen : Site Reference ID/Investigator# 33436
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bautzen : Site Reference ID/Investigator# 30815
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bautzen : Site Reference ID/Investigator# 30330
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bayreuth :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Bayreuth : Site Reference ID/Investigator# 33442
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bayreuth : Site Reference ID/Investigator# 33446
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bayreuth : Site Reference ID/Investigator# 33440
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bayreuth : Site Reference ID/Investigator# 30443
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bayreuth : Site Reference ID/Investigator# 30424
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Belm : Site Reference ID/Investigator# 53978
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bensheim : Site Reference ID/Investigator# 33449
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bensheim : Site Reference ID/Investigator# 29883
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Berlin :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Berlin :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Berlin :
An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis
Berlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Berlin : Study Site (Berlin 1)
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Berlin : Study Site (Berlin 2)
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Berlin : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Berlin : Site Reference ID/Investigator# 35597
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35089
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 34246
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33620
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33648
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33661
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33683
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33687
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33693
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33641
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33658
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33670
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33690
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33697
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33704
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Ref # / Investigator 33674
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 34238
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35527
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35550
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35551
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 34269
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33662
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33672
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33685
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33695
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 34243
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53959
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53884
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33646
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33681
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 33688
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53948
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53933
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53939
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53971
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 53902
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35599
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 35552
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Site Reference ID/Investigator# 34260
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin : Investigational Site Number 276008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Berlin : Investigational Site Number 276009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Berlin : Investigational Site Number 276010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Berlin : Investigational Site Number 276007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Berlin : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Berlin : Site Reference ID/Investigator# 29866
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 53385
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 49313
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30394
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30288
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30290
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30246
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 49253
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 64823
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 53406
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 64826
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator 30234
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 51050
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 51074
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 51108
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Ref # / Investigator 53387
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30396
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30707
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30462
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin : Site Reference ID/Investigator# 30218
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin :
Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis
Berlin :
Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
Berlin-Buch : Site Reference ID/Investigator# 34266
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin-Buch : Site Reference ID/Investigator# 34264
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin-Buch : Site Ref # / Investigator 53608
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Berlin-Wannsee : Site Reference ID/Investigator# 34252
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Berlin-Wannsee : Site Reference ID/Investigator# 34250
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Berlin-Wannsee : Site Ref # / Investigator 53390
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bernau : Site Reference ID/Investigator# 35556
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bernau : Site Reference ID/Investigator# 35554
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bernau : Site Reference ID/Investigator# 30713
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Biberach : Site Reference ID/Investigator# 34277
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Biberach : Site Reference ID/Investigator# 53899
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bielefeld : Site Reference ID/Investigator# 34279
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bietigheim-Bissingen : Site Reference ID/Investigator# 35559
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bietigheim-Bissingen : Site Reference ID/Investigator# 35560
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bietigheim-Bissingen : Site Reference ID/Investigator# 49303
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Binzen : Site Reference ID/Investigator# 35562
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Blankenburg/Hart : Site Reference ID/Investigator# 34285
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Blankenburg/Hart : Site Reference ID/Investigator# 34283
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Blaubeuren :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Blaubeuren : Site Reference ID/Investigator# 34288
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Blaubeuren : Site Reference ID/Investigator# 34286
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Blaubeuren : Site Reference ID/Investigator# 30817
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bocholt : Site Reference ID/Investigator# 35566
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bocholt : Site Reference ID/Investigator# 34291
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bocholt : Site Reference ID/Investigator# 53946
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bocholt : Site Reference ID/Investigator# 34289
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bochum : Site Reference ID/Investigator# 35641
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bochum : Site Reference ID/Investigator# 35567
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bochum : Site Reference ID/Investigator# 49287
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bogen : Site Reference ID/Investigator# 35644
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bogen : Site Reference ID/Investigator# 35642
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bogen : Site Reference ID/Investigator# 30306
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bonn : Site Reference ID/Investigator# 34296
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 34302
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 35646
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bonn : Site Ref # / Investigator 34300
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 34294
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 53969
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 35647
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 35648
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bonn : Site Reference ID/Investigator# 30279
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bonn : Site Reference ID/Investigator# 49302
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bonn : Site Ref # / Investigator 53404
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bottrop : Site Reference ID/Investigator# 35652
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Braunschweig : Site Reference ID/Investigator# 34307
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Braunschweig : Site Reference ID/Investigator# 34305
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Braunschweig : Site Reference ID/Investigator# 34310
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Braunschweig : Site Reference ID/Investigator# 49284
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Braunschweig : Site Reference ID/Investigator# 30264
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Breitenbrunn : Site Reference ID/Investigator# 35603
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Breitenbrunnd : Site Reference ID/Investigator# 35601
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bremen : Site Reference ID/Investigator# 35609
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Bremen : Site Reference ID/Investigator# 35607
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bremen : Site Reference ID/Investigator# 53975
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Bremen : Site Reference ID/Investigator# 29875
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Bruchhausen-vilsen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Buechen : Site Reference ID/Investigator# 53934
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Celle : Site Reference ID/Investigator# 35611
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Celle : Site Reference ID/Investigator# 34696
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Chemnitz :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Chemnitz : Site Reference ID/Investigator# 35093
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Chemnitz : Site Reference ID/Investigator# 34699
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Chemnitz : Site Reference ID/Investigator# 35092
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Chemnitz : Site Reference ID/Investigator# 34700
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Chemnitz : Site Reference ID/Investigator# 30284
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Chemnitz : Site Reference ID/Investigator# 29807
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Coesfeld : Site Reference ID/Investigator# 35615
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 35237
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 33989
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 33987
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 33996
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 33990
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 33993
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cologne : Site Reference ID/Investigator# 35238
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cologne : Site Ref # / Investigator 53409
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Cologne : Site Ref # / Investigator 53391
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Cottbus : Site Reference ID/Investigator# 34708
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Cottbus : Site Reference ID/Investigator# 34711
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Cottbus : Site Reference ID/Investigator# 35617
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cottbus : Site Reference ID/Investigator# 30812
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Cottbus : Site Reference ID/Investigator# 30344
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Cuxhaven :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Cuxhaven : Site Reference ID/Investigator# 53889
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Cuxhaven : Site Reference ID/Investigator# 53987
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Damp : Site Reference ID/Investigator# 34718
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Damp : Site Reference ID/Investigator# 34715
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Damp : Site Reference ID/Investigator# 30780
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Darmstadt : Site Reference ID/Investigator# 35621
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Darmstadt : Site Reference ID/Investigator# 35622
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Darmstadt : Site Reference ID/Investigator# 30318
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Darmstadt : Site Reference ID/Investigator# 29983
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Deggendorf : Site Reference ID/Investigator# 34725
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Deggendorf : Site Reference ID/Investigator# 30382
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Delmenhorst : Site Reference ID/Investigator# 53885
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Demmin : Site Reference ID/Investigator# 34726
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Denkendorf : Site Reference ID/Investigator# 53932
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dessau-Rosslau : Site Reference ID/Investigator# 35631
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dessau-Rosslau : Site Reference ID/Investigator# 49272
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Dortmund : Site Reference ID/Investigator# 34742
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dortmund : Site Reference ID/Investigator# 35634
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dortmund : Site Reference ID/Investigator# 35635
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dortmund : Site Reference ID/Investigator# 35632
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dortmund : Site Reference ID/Investigator# 35636
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Dresden :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Dresden : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Dresden : Site Reference ID/Investigator# 34760
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34748
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34751
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34754
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 35170
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34762
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34763
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 53958
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 34749
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 35171
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Dresden : Site Reference ID/Investigator# 49244
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Dresden : Site Reference ID/Investigator# 49283
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Dresden : Site Reference ID/Investigator# 30256
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Dresden : Site Reference ID/Investigator# 30390
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Dresden : Site Reference ID/Investigator# 30703
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Duesseldorf : Site Reference ID/Investigator# 34773
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Duesseldorf : Site Reference ID/Investigator# 34768
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Duesseldorf : Site Reference ID/Investigator# 34774
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Duesseldorf : Site Reference ID/Investigator# 34771
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Duesseldorf : Site Reference ID/Investigator# 49278
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Duesseldorf : Site Ref # / Investigator 51107
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Duisburg : Site Reference ID/Investigator# 34778
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Duisburg : Site Reference ID/Investigator# 53897
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Duisburg : Site Ref # / Investigator 34776
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Duisburg : Site Reference ID/Investigator# 29813
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ebensfeld : Site Reference ID/Investigator# 34779
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Eberswalde : Site Reference ID/Investigator# 34784
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Eberswalde : Site Reference ID/Investigator# 34782
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Eberswalde : Site Reference ID/Investigator# 49290
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Eisenbergngen : Site Reference ID/Investigator# 54805
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Elmshorn : Site Reference ID/Investigator# 35184
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Elmshorn : Site Reference ID/Investigator# 35180
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Elmshorn : Site Reference ID/Investigator# 30298
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Emmerich : Site Reference ID/Investigator# 49258
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Erfstadt : Site Reference ID/Investigator# 34802
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Erfurt :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Erfurt : Site Reference ID/Investigator# 35191
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Erfurt : Site Reference ID/Investigator# 35096
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Erfurt : Site Reference ID/Investigator# 34809
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Erfurt : Site Reference ID/Investigator# 35189
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Erfurt : Site Reference ID/Investigator# 35097
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Erfurt : Site Reference ID/Investigator# 30722
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Erfurt : Site Reference ID/Investigator# 30364
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Erlangen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Erlangen :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Erlangen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Erlangen : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Erlangen : Site Reference ID/Investigator# 34821
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Erlangen : Site Ref # / Investigator 54811
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Erlangen : Site Reference ID/Investigator# 34815
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Erlangen : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Erlangen : Investigational Site Number 276004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Essen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Essen : Site Reference ID/Investigator# 35196
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 35199
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 53931
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 34823
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 35194
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 53925
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Essen : Site Reference ID/Investigator# 49268
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Essen : Site Reference ID/Investigator# 30740
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Esslingen : Site Reference ID/Investigator# 34829
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Feldafing : Site Reference ID/Investigator# 35202
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Feldafing : Site Reference ID/Investigator# 35200
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Flensburg : Site Reference ID/Investigator# 35205
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Flensburg : Site Reference ID/Investigator# 35203
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Forchheim : Site Reference ID/Investigator# 34833
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Forchheim : Site Reference ID/Investigator# 34831
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Forchheim : Site Reference ID/Investigator# 30376
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankenberg : Site Reference ID/Investigator# 35210
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Frankenberg : Site Reference ID/Investigator# 30252
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Frankfurt :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Frankfurt : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Frankfurt : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Frankfurt : Site Reference ID/Investigator# 34840
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Frankfurt : Site Reference ID/Investigator# 34849
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Frankfurt : Site Reference ID/Investigator# 34843
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Frankfurt : Site Reference ID/Investigator# 34838
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Frankfurt : Site Reference ID/Investigator# 34851
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Frankfurt : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Frankfurt : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Frankfurt : Site Reference ID/Investigator# 30260
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt : Site Reference ID/Investigator# 30248
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt : Site Reference ID/Investigator# 49247
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt : Site Reference ID/Investigator# 49286
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt : Site Reference ID/Investigator# 49260
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Frankfurt Am Main : Investigational Site Number 276003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Frankfurt am Main : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Fraureuth : Site Reference ID/Investigator# 35213
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Fraureuth : Site Reference ID/Investigator# 35211
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiberg : Site Reference ID/Investigator# 35219
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Freiberg : Site Reference ID/Investigator# 35217
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiberg : Site Reference ID/Investigator# 30366
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Freiburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Freiburg : Site Reference ID/Investigator# 34854
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 34861
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 35221
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 34852
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 34855
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 34859
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiburg : Site Reference ID/Investigator# 53926
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Freiburg : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Freiburg : Site Reference ID/Investigator# 49294
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Freiburg : Site Reference ID/Investigator# 51099
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Freiburg : Site Reference ID/Investigator# 29810
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Freystadt : Site Reference ID/Investigator# 35101
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Freystadt : Site Reference ID/Investigator# 35099
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Friedberg : Site Reference ID/Investigator# 53960
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Friedrichroda : Site Reference ID/Investigator# 35224
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Friedrichroda : Site Reference ID/Investigator# 35222
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Friedrichroda : Site Ref # / Investigator 51047
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Geesthacht : Site Reference ID/Investigator# 53976
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Geesthacht : Site Reference ID/Investigator# 49307
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Geilenkirchen : Site Reference ID/Investigator# 53890
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Gelsenkirchen : Site Reference ID/Investigator# 34879
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Gelsenkirchen : Site Ref # / Investigator 34877
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Gera : Site Reference ID/Investigator# 34883
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
GieBen : Site Reference ID/Investigator# 34887
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Gielefeld : Site Ref # / Investigator 54810
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Giessen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Giessen : Site Reference ID/Investigator# 53909
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Gladbeck : Site Reference ID/Investigator# 53922
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Gladbeck : Site Reference ID/Investigator# 49273
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Goettingen : Site Ref # / Investigator 65622
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Goettingen : Site Reference ID/Investigator# 35231
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Gommern :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Gosheim : Site Reference ID/Investigator# 35491
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Goslar : Site Reference ID/Investigator# 34896
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Goslar : Site Reference ID/Investigator# 34894
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Göttingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Göttingen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Grafelfing : Site Reference ID/Investigator# 30368
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Gräfelfing :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Greifswald : Site Reference ID/Investigator# 34904
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Greifswald : Site Reference ID/Investigator# 35496
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Greifswald : Site Reference ID/Investigator# 34901
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Greifswald : Site Reference ID/Investigator# 34902
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Greifswald : Site Reference ID/Investigator# 49259
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Greifswald : Site Reference ID/Investigator# 49256
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Greifswald : Site Reference ID/Investigator# 30328
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Guben : Site Reference ID/Investigator# 35498
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Guestrow : Site Reference ID/Investigator# 34910
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Guestrow : Site Reference ID/Investigator# 30404
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Gustrow : Site Reference ID/Investigator# 34912
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hagen : Site Reference ID/Investigator# 35503
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hagen : Site Reference ID/Investigator# 35501
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Halle :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Halle : Site Reference ID/Investigator# 34937
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34940
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34922
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34932
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34944
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Halle : Site Ref # / Investigator 33819
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34924
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34920
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34935
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34938
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 34942
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Halle : Site Reference ID/Investigator# 30729
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Halle : Site Reference ID/Investigator# 30452
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 34955
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34958
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34970
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34983
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34994
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35441
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35449
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35111
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35444
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35452
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34952
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34961
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34974
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34986
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34998
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35000
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35007
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34946
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34959
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34965
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34977
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34984
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34996
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 33578
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35442
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35450
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 53984
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 54806
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Ref # / Investigator 34967
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 33367
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34956
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34962
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35112
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34981
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 34989
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 35001
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Site Reference ID/Investigator# 53900
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hamburg : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hamburg : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hamburg : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Hamburg : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hamburg : Investigational Site Number 276005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Hamburg : Frank Lampe, MD
Minimally Invasive Versus Conventional Approaches in Navigated Total Knee Arthroplasty (TKA)
Hamburg : Site Reference ID/Investigator# 30392
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30400
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30739
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30702
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30715
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30716
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30797
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30340
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30346
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30286
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30292
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 49245
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30818
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 30821
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 49295
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 49280
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 49312
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamburg : Site Reference ID/Investigator# 29833
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hamm : Site Reference ID/Investigator# 53953
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hanau : Site Reference ID/Investigator# 35019
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hanau : Site Reference ID/Investigator# 35017
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hanau : Site Reference ID/Investigator# 30270
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hannover :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Hannover : Site Reference ID/Investigator# 35025
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hannover : Site Reference ID/Investigator# 33712
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hannover : Site Reference ID/Investigator# 33713
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hannover : Site Reference ID/Investigator# 35021
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hannover : Site Reference ID/Investigator# 35032
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hannover : Site Reference ID/Investigator# 33788
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hannover : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Hannover : Site Reference ID/Investigator# 30262
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hannover : Site Reference ID/Investigator# 30029
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hanover : Site Ref # / Investigator 53393
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Harrislee : Site Reference ID/Investigator# 33792
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Harrislee : Site Reference ID/Investigator# 33790
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Haseluenne : Site Reference ID/Investigator# 35459
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Haseluenne : Site Ref # / Investigator 65629
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hattingen : Site Reference ID/Investigator# 33795
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Heidelberg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Heidelberg :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 33798
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33808
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 35119
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33801
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33813
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33806
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33796
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Heidelberg : Site Reference ID/Investigator# 33811
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Heidelberg : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Heidelberg : Investigational Site Number 276012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Heidelberg : Site Ref # / Investigator 53388
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 30254
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 30701
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 30448
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 30451
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidelberg : Site Reference ID/Investigator# 49282
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Heidenheim : Site Reference ID/Investigator# 35464
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heilbad Hailigenstadt : Site Reference ID/Investigator# 33816
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Heilbad Heiligenstadt : Site Reference ID/Investigator# 33818
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Heilbad Heiligenstadt : Site Reference ID/Investigator# 49292
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Herne : Site Reference ID/Investigator# 53911
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Herne : Site Ref # / Investigator 65623
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Herne : Site Reference ID/Investigator# 53910
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Herne : Investigational Site Number 276001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Herne : Site Ref # / Investigator 53407
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Herrsching : Site Reference ID/Investigator# 33825
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Herrsching : Site Reference ID/Investigator# 33823
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Herrsching : Site Reference ID/Investigator# 30737
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hildesheim : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Hildesheim : Site Reference ID/Investigator# 33831
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hildesheim : Investigational Site Number 276006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Hildesheim : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Hildesheim : Site Reference ID/Investigator# 49308
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hof : Site Reference ID/Investigator# 33834
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hof : Site Reference ID/Investigator# 33836
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hofheim : Site Reference ID/Investigator# 33842
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hofheim : Site Reference ID/Investigator# 33840
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Hofheim : Site Reference ID/Investigator# 49285
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Hohenfelde : Site Reference ID/Investigator# 33845
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Hohenfelde : Site Reference ID/Investigator# 33843
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Homburg : Site Reference ID/Investigator# 54807
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
IIIertissen : Site Reference ID/Investigator# 33855
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Illingen : Site Reference ID/Investigator# 53985
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Immenstadt : Site Reference ID/Investigator# 33858
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Immenstadt : Site Reference ID/Investigator# 49252
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ingolstadt : Site Reference ID/Investigator# 35479
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ingolstadt : Site Reference ID/Investigator# 33933
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ingolstadt : Site Reference ID/Investigator# 29877
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Jena :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Jena : Site Reference ID/Investigator# 51882
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Jena : Site Reference ID/Investigator# 5323
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Jena : Site Reference ID/Investigator# 53938
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Jena : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Jena : Site Reference ID/Investigator# 49289
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Jena : Site Reference ID/Investigator# 49242
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Juelich : Site Reference ID/Investigator# 33940
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Juelich : Site Reference ID/Investigator# 49274
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Julich : Site Reference ID/Investigator# 33942
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kahla : Site Reference ID/Investigator# 33946
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kahla : Site Reference ID/Investigator# 35125
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kahla : Site Reference ID/Investigator# 33944
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kahla : Site Reference ID/Investigator# 35124
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kahla : Site Reference ID/Investigator# 30453
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kahla : Site Reference ID/Investigator# 30454
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kaiserslautern : Site Reference ID/Investigator# 33950
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kaiserslautern : Site Reference ID/Investigator# 33948
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kaiserslautern : Site Reference ID/Investigator# 69462
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kaltenkirchen : Site Reference ID/Investigator# 53935
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Karlsruhe : Site Reference ID/Investigator# 33956
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Karlsruhe : Site Reference ID/Investigator# 33961
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Karlsruhe : Site Reference ID/Investigator# 33954
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Karlsruhe : Site Reference ID/Investigator# 33397
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Karlsruhe : Site Reference ID/Investigator# 30374
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Karlsruhe : Site Reference ID/Investigator# 30711
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Karlsruhe : Site Reference ID/Investigator# 30410
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Karlstadt : Site Reference ID/Investigator# 35482
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Karlstadt : Site Reference ID/Investigator# 49306
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kassel : Site Reference ID/Investigator# 33964
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kassel : Site Reference ID/Investigator# 33962
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kiel :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Kiel : Site Reference ID/Investigator# 29855
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Koeln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Koeln : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Koeln : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Koenigs Wusterhausen : Site Reference ID/Investigator# 34000
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kolkwitz : Site Reference ID/Investigator# 35239
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Koln : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Köln :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Köln :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Konigs Wusterhausen : Site Reference ID/Investigator# 34002
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Konigs Wusterhausen : Site Reference ID/Investigator# 30412
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kressbronn : Site Reference ID/Investigator# 34008
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kressbronn : Site Reference ID/Investigator# 34006
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kressbronn : Site Reference ID/Investigator# 49257
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Kronach : Site Reference ID/Investigator# 34084
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Kronach : Site Reference ID/Investigator# 34009
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kyritz : Site Reference ID/Investigator# 34086
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Kyritz : Site Reference ID/Investigator# 49311
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Lahr : Site Reference ID/Investigator# 34005
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Lahr : Site Reference ID/Investigator# 34003
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Landau : Site Reference ID/Investigator# 35245
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Landau : Site Reference ID/Investigator# 30240
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 34100
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 34106
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 34109
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 34112
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Leipzig : Site Ref # / Investigator 65628
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 34098
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 34107
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Leipzig : Site Reference ID/Investigator# 53937
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Leipzig : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Leipzig : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Leipzig : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Leipzig : Site Reference ID/Investigator# 49298
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 30282
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 30456
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 30356
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 30455
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 49250
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leipzig : Site Reference ID/Investigator# 49310
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Leverkusen : Site Reference ID/Investigator# 34119
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lichtenstein : Site Reference ID/Investigator# 34121
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lichtenstein : Site Reference ID/Investigator# 30332
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Lingen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Lippstadt : Site Reference ID/Investigator# 35254
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Lippstadt : Site Reference ID/Investigator# 35252
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lohne : Site Reference ID/Investigator# 53882
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lubeck : Site Reference ID/Investigator# 34136
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ludwigsburg : Site Reference ID/Investigator# 53886
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ludwigsfelde :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Ludwigsfelde : Site Reference ID/Investigator# 35260
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ludwigsfelde : Site Reference ID/Investigator# 35257
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ludwigsfelde : Site Reference ID/Investigator# 30320
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ludwigshafen : Site Reference ID/Investigator# 35262
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ludwigshafen : Site Ref # / Investigator 51042
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ludwigslust : Site Reference ID/Investigator# 53906
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ludwigslust : Site Ref # / Investigator 53392
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Luebeck : Site Reference ID/Investigator# 34133
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Luebeck : Site Reference ID/Investigator# 49281
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Luedenscheid : Site Reference ID/Investigator# 53943
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lueneburg : Site Reference ID/Investigator# 34139
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Lueneburg : Site Reference ID/Investigator# 33407
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lueneburg : Site Reference ID/Investigator# 53888
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Lueneburg : Site Reference ID/Investigator# 30728
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Madgeburg : Site Reference ID/Investigator# 53913
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Madgeburg : Site Reference ID/Investigator# 34148
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Magdeburg : Site Reference ID/Investigator# 34147
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Magdeburg : Site Reference ID/Investigator# 34150
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Magdeburg : Site Reference ID/Investigator# 53981
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Magdeburg : Site Reference ID/Investigator# 30813
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Magdeburg : Site Reference ID/Investigator# 29852
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Mainz : Site Reference ID/Investigator# 35276
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Mainz : Site Reference ID/Investigator# 34154
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Mainz : Site Ref # / Investigator 65631
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Mainz : Site Reference ID/Investigator# 53928
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Mainz : Site Reference ID/Investigator# 49297
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Mannheim : Site Reference ID/Investigator# 34184
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Marktredwitz : Site Reference ID/Investigator# 34192
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Marktredwitz : Site Reference ID/Investigator# 22001
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Marl : Site Reference ID/Investigator# 34196
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Marl : Site Reference ID/Investigator# 34194
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Marl : Site Reference ID/Investigator# 29831
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Meissen : Site Reference ID/Investigator# 34200
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Menz : Site Reference ID/Investigator# 35285
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Menz : Site Reference ID/Investigator# 35283
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Menz : Site Reference ID/Investigator# 30266
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Merxheim : Site Reference ID/Investigator# 53896
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Minden : Site Reference ID/Investigator# 35287
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Minden : Site Reference ID/Investigator# 33418
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Minden : Site Reference ID/Investigator# 49277
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Mittelherwigsdorf : Site Reference ID/Investigator# 34208
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Mittelherwigsdorf : Site Reference ID/Investigator# 34206
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Mittelherwigsdorf : Site Reference ID/Investigator# 30238
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Moenchengladbach : Site Reference ID/Investigator# 34211
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Moenchengladbach : Site Reference ID/Investigator# 34214
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Moenchengladbach : Site Reference ID/Investigator# 34216
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Moenchengladbach : Site Reference ID/Investigator# 53915
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Moenchengladbach : Site Ref # / Investigator 51109
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Moenkeberg : Site Reference ID/Investigator# 34219
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Monchengladbach : Site Reference ID/Investigator# 34213
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Monchengladbach : Site Reference ID/Investigator# 34218
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Monkeberg : Site Reference ID/Investigator# 34221
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Monkeberg : Site Reference ID/Investigator# 49248
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Muelheim : Site Reference ID/Investigator# 35292
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Muelheim : Site Reference ID/Investigator# 49299
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Muenchen : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Muenchen : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Muenchen : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Muenchen : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Muenster : Site Reference ID/Investigator# 34048
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Muenster : Site Reference ID/Investigator# 34044
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Muenster : Site Reference ID/Investigator# 34046
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Muenster : Site Reference ID/Investigator# 53970
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Muenster : Site Reference ID/Investigator# 30710
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Muenster : Site Reference ID/Investigator# 49262
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Muhlhausen : Site Reference ID/Investigator# 34224
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Mullheim : Site Reference ID/Investigator# 34229
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Mullheim : Site Reference ID/Investigator# 49251
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Munchen : Site Reference ID/Investigator# 34232
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munchen : Site Reference ID/Investigator# 34043
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munchen : Krankenhaus Munchen Bogenhausen
Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder
München :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
München :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
München : Study site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
München : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Munich : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Munich : Site Reference ID/Investigator# 35295
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 34040
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 34235
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 35298
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 34041
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 53912
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 53956
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 53962
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 53924
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 53904
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 35296
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 34035
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Reference ID/Investigator# 34037
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Munich : Site Ref # / Investigator 53607
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Munich : Site Ref # / Investigator 53396
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Munich : Site Ref # / Investigator 53397
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Munich : Site Ref # / Investigator 53401
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Münster :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Naumburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Naumburg : Site Reference ID/Investigator# 35306
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Naunhof :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Naunhof : Site Reference ID/Investigator# 34052
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Naunhof : Site Reference ID/Investigator# 34050
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Naunhof : Site Reference ID/Investigator# 49249
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neubrandenburg : Site Reference ID/Investigator# 34061
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Neubrandenburg : Site Reference ID/Investigator# 34059
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Neubrandenburg : Site Reference ID/Investigator# 29812
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neuburg : Site Reference ID/Investigator# 34062
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Neuburg : Site Reference ID/Investigator# 30719
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neuburg 86633 : Site Reference ID/Investigator# 34064
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Neumunster : Site Reference ID/Investigator# 34071
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Neunkirchen : Site Reference ID/Investigator# 34980
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Neunkirchen : Site Reference ID/Investigator# 49254
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neuss :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Neuss : Site Reference ID/Investigator# 35313
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Neuss : Site Reference ID/Investigator# 35311
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Neuss : Site Ref # / Investigator 53389
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neustadt : Site Reference ID/Investigator# 34076
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Neustadt : Site Reference ID/Investigator# 34072
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Neustadt : Site Reference ID/Investigator# 30731
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Neuwied : Site Ref # / Investigator 65630
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Niederbrombach : Site Reference ID/Investigator# 35321
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Niefern : Site Reference ID/Investigator# 30439
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Niefern-Oeschelbronn : Site Reference ID/Investigator# 34078
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Niefern-Oschelbronn : Site Reference ID/Investigator# 34080
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Nienburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Nienburg : Site Reference ID/Investigator# 34158
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Nienburg : Site Reference ID/Investigator# 34081
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Nienburg : Site Reference ID/Investigator# 34082
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Nienburg : Site Reference ID/Investigator# 30460
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Nienburg : Site Reference ID/Investigator# 30459
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Nuernberg : Site Reference ID/Investigator# 53923
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Nuremburg : Site Ref # / Investigator 51067
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Nurnberg : Site Reference ID/Investigator# 30704
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Nürnberg : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Oberammergau : Site Ref # / Investigator 51056
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Oberguenzburg : Site Reference ID/Investigator# 34168
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Oelsnitz : Site Reference ID/Investigator# 34173
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Offenburg : Site Reference ID/Investigator# 34176
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Offenburg : Site Reference ID/Investigator# 34174
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Offenburg : Site Reference ID/Investigator# 49243
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Oldenburg : Site Reference ID/Investigator# 33492
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Oldenburg : Site Reference ID/Investigator# 33490
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Oldenburg : Site Reference ID/Investigator# 30268
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Olsberg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Olsberg : Site Reference ID/Investigator# 53950
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Osnabrück :
An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN)
Osnabrueck : Site Reference ID/Investigator# 54803
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Osnabrueck : Site Reference ID/Investigator# 33499
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Osnabrueck : Site Ref # / Investigator 51046
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Paderborn : Site Reference ID/Investigator# 35335
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Paderborn : Site Reference ID/Investigator# 35333
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Paderborn : Site Ref # / Investigator 51102
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Papenburg : Site Reference ID/Investigator# 33503
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Parchim : Site Reference ID/Investigator# 33508
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Parchim : Site Reference ID/Investigator# 33506
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Parchim : Site Reference ID/Investigator# 30402
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Parsberg : Site Reference ID/Investigator# 33509
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Passau : Site Reference ID/Investigator# 35340
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Passau : Site Reference ID/Investigator# 35338
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Passau : Site Reference ID/Investigator# 30718
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Petershagen : Site Reference ID/Investigator# 33511
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Pfullendorf : Site Reference ID/Investigator# 33517
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Pinneberg : Site Reference ID/Investigator# 33519
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Pirna : Site Reference ID/Investigator# 33520
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Pirna : Site Reference ID/Investigator# 30700
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Planegg : Site Reference ID/Investigator# 33523
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Planegg : Site Reference ID/Investigator# 33521
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Planegg : Site Reference ID/Investigator# 30206
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Plauen : Site Reference ID/Investigator# 33528
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Plauen : Site Reference ID/Investigator# 33526
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Plauen : Site Reference ID/Investigator# 30816
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Plochingen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Potsdam :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Potsdam : Site Reference ID/Investigator# 33466
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Potsdam : Site Reference ID/Investigator# 33470
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Potsdam : Site Reference ID/Investigator# 33468
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Potsdam : Site Reference ID/Investigator# 33464
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Potsdam : Site Reference ID/Investigator# 30441
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Potsdam : Site Reference ID/Investigator# 30790
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Prum : Site Reference ID/Investigator# 33476
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Prum : Site Reference ID/Investigator# 30352
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Puettlingen : Site Reference ID/Investigator# 33479
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Pulheim : Site Reference ID/Investigator# 53940
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Radebeul : Site Reference ID/Investigator# 33484
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Radebeul : Site Reference ID/Investigator# 35347
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Radebeul : Site Reference ID/Investigator# 33482
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Radebeul : Site Reference ID/Investigator# 30408
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Raststatt : Site Reference ID/Investigator# 53964
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ratingen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Ratingen : Site Reference ID/Investigator# 35136
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ratingen : Site Reference ID/Investigator# 35134
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ratingen : Site Reference ID/Investigator# 54812
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ratingen : Site Ref # / Investigator 33485
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ratingen : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ratingen : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Ratingen : Site Reference ID/Investigator# 49309
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ratingen : Site Ref # / Investigator 64848
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ratzeburg : Site Reference ID/Investigator# 33488
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ratzeburg : Site Reference ID/Investigator# 30416
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Regensburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Regensburg : Site Reference ID/Investigator# 33883
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33890
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33886
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33881
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33891
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33884
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 33888
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 53930
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Regensburg : Site Reference ID/Investigator# 30736
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Reichenbach : Site Reference ID/Investigator# 51885
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Reichenbach : Site Reference ID/Investigator# 53986
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Reichenbach : Site Ref # / Investigator 64827
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Reichenbach : Site Ref # / Investigator 64824
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Reken : Site Reference ID/Investigator# 33897
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Reken : Site Reference ID/Investigator# 53957
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Reken : Site Reference ID/Investigator# 30738
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Remscheid : Site Reference ID/Investigator# 53920
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rendsburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Rendsburg : Site Reference ID/Investigator# 33902
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rendsburg : Site Reference ID/Investigator# 33900
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rendsburg : Site Reference ID/Investigator# 30316
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Reutlingen : Site Reference ID/Investigator# 33903
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rheine :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Rheine : Site Reference ID/Investigator# 33907
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rheine : Site Reference ID/Investigator# 30720
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Rheine : Site Ref # / Investigator 53605
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Rheinfelden : Site Reference ID/Investigator# 53982
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rickenbach : Site Reference ID/Investigator# 35355
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rickenbach : Site Reference ID/Investigator# 53908
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Riesa : Site Reference ID/Investigator# 33911
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Riesa : Site Reference ID/Investigator# 33393
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Riesa : Site Reference ID/Investigator# 30322
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Rinteln : Site Reference ID/Investigator# 33914
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rinteln : Site Reference ID/Investigator# 33912
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Roehrnbach : Site Reference ID/Investigator# 33916
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rostock :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Rostock :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Rostock : Site Reference ID/Investigator# 33927
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rostock : Site Reference ID/Investigator# 33923
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rostock : Site Reference ID/Investigator# 33921
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Rostock : Site Reference ID/Investigator# 30358
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Rostock : Site Reference ID/Investigator# 30447
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Rothenburg : Site Reference ID/Investigator# 33931
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Rothenburg : Site Reference ID/Investigator# 33929
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ruedersdorf : Site Reference ID/Investigator# 35362
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ruedersdorf : Site Reference ID/Investigator# 49276
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Saarbrücken :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Saarbruecken : Site Reference ID/Investigator# 34016
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Saarbruecken : Site Reference ID/Investigator# 34014
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Saarbruecken : Site Reference ID/Investigator# 30819
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Salzwedel : Site Reference ID/Investigator# 34023
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Salzwedel : Site Reference ID/Investigator# 34021
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Salzwedel : Site Reference ID/Investigator# 30709
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Sande : Site Reference ID/Investigator# 34027
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schlangenbad : Site Reference ID/Investigator# 53916
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Schneeberg : Site Reference ID/Investigator# 33534
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schneeberg : Site Reference ID/Investigator# 34030
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Schramberg : Site Reference ID/Investigator# 33539
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schramberg : Site Reference ID/Investigator# 30314
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Schutterwald : Site Reference ID/Investigator# 33542
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schwandorf : Site Reference ID/Investigator# 35371
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schwerin : Site Reference ID/Investigator# 33549
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schwerin : Site Reference ID/Investigator# 35376
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schwerin : Site Reference ID/Investigator# 33550
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Schwerin : Site Reference ID/Investigator# 35374
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Schwerin : Site Reference ID/Investigator# 30244
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Schwerin : Site Reference ID/Investigator# 30276
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Schwerin : Site Ref # / Investigator 51070
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Schwerte : Site Reference ID/Investigator# 33555
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Schwerte : Site Reference ID/Investigator# 33553
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Seesen : Site Reference ID/Investigator# 33559
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Seesen : Site Reference ID/Investigator# 33557
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Seesen : Site Reference ID/Investigator# 30236
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Senden : Site Reference ID/Investigator# 33563
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Sendenhorst :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Siegen : Site Reference ID/Investigator# 53944
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Siegen : Site Reference ID/Investigator# 53945
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Singen : Site Reference ID/Investigator# 35380
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Singen : Site Reference ID/Investigator# 49305
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Sinsheim : Site Reference ID/Investigator# 33567
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Sinsheim : Site Reference ID/Investigator# 33565
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Sinsheim : Site Reference ID/Investigator# 30388
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Solingen : Site Reference ID/Investigator# 53927
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Soltau : Site Reference ID/Investigator# 33572
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Soltau : Site Reference ID/Investigator# 33570
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Soltau : Site Reference ID/Investigator# 30418
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Spremberg : Site Reference ID/Investigator# 33577
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
St. Martin : Site Reference ID/Investigator# 35383
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stadtbergen : Site Reference ID/Investigator# 33583
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stadthagen : Site Reference ID/Investigator# 33588
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stadthagen : Site Reference ID/Investigator# 33586
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stadthagen : Site Reference ID/Investigator# 49267
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Steinhagen : Site Reference ID/Investigator# 33592
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Steinhagennnd : Site Reference ID/Investigator# 53936
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stuttgart :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Stuttgart : Site Reference ID/Investigator# 33604
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33598
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33607
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33611
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33596
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33602
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 33609
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Stuttgart : Site Reference ID/Investigator# 49291
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Stuttgart : Site Reference ID/Investigator# 49265
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Suhl : Site Reference ID/Investigator# 35389
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Suhl : Site Reference ID/Investigator# 35387
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Suhl : Site Reference ID/Investigator# 49255
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Tarp : Site Reference ID/Investigator# 54808
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Tegernau : Site Reference ID/Investigator# 35391
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Thum-Jahnsbach : Site Reference ID/Investigator# 35433
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Tischenreuth : Site Reference ID/Investigator# 53951
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Torgelow : Site Reference ID/Investigator# 33625
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Torgelow : Site Reference ID/Investigator# 33623
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Torgelow : Site Reference ID/Investigator# 30384
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Traunstein :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Treuenbrietzen : Site Ref # / Investigator 33628
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Treuenbrietzen : Site Reference ID/Investigator# 30712
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Treuenbrietzen : Site Ref # / Investigator 51101
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Tübingen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Tuebingen : Site Reference ID/Investigator# 53907
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Tuebingen : Site Reference ID/Investigator# 49269
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Twistringen : Site Reference ID/Investigator# 53893
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ueberlingen : Site Reference ID/Investigator# 33637
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ueberlingen : Site Reference ID/Investigator# 33635
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ueberlingen : Site Reference ID/Investigator# 30024
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Uffenheim : Site Reference ID/Investigator# 35395
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Uhlstaedt-Kirchhasellow : Site Reference ID/Investigator# 53898
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ulm : Germany Site Reference ID/Investigator# 33724
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ulm : Site Reference ID/Investigator# 33721
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Ulm : Site Ref # / Investigator 65626
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ulm : Site Reference ID/Investigator# 33722
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Ulm : Site Reference ID/Investigator# 30370
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Ulm : Site Ref # / Investigator 51062
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Verden : Site Reference ID/Investigator# 33732
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Viersen : Site Reference ID/Investigator# 33734
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Viersen : Site Reference ID/Investigator# 53965
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Villingen : Site Reference ID/Investigator# 33737
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Villingen-schwenningen :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Villingen-schwenningen :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Villingen-Schwenningen : Site Reference ID/Investigator# 33735
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Villingen-Schwenningen : Site Reference ID/Investigator# 30274
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Voehringen : Site Reference ID/Investigator# 35397
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Vogelsang-Gommern : Site Reference ID/Investigator# 53914
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Vreden : Site Reference ID/Investigator# 53952
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Waldbronn : Site Reference ID/Investigator# 54809
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Waltrop : Site Reference ID/Investigator# 33742
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Waltrop : Site Reference ID/Investigator# 33740
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Waltrop : Site Reference ID/Investigator# 30732
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Weener : Site Reference ID/Investigator# 33747
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Weener : Site Reference ID/Investigator# 30378
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Weener 26826 : Site Reference ID/Investigator# 33749
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
WeiBenfels : Site Reference ID/Investigator# 33751
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Weiden i.d. Oberpfalz : Site Reference ID/Investigator# 53891
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Weissenfels : Site Reference ID/Investigator# 53921
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Weissenfels : Site Reference ID/Investigator# 29825
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Welzow : Site Reference ID/Investigator# 33852
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Welzow : Site Reference ID/Investigator# 33753
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Welzow : Site Reference ID/Investigator# 30133
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wiefelstede : Site Reference ID/Investigator# 35404
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 33761
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 35408
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 35413
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 33765
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 35406
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 33762
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 53941
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wiesbaden : Site Reference ID/Investigator# 30278
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wiesbaden : Site Reference ID/Investigator# 49300
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wiesbaden : Site Reference ID/Investigator# 49246
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wiesbaden : Site Reference ID/Investigator# 30420
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wiesbaden : Site Ref # / Investigator 64825
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wilhelmshaven : Site Reference ID/Investigator# 33772
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wilhelmshaven : Site Reference ID/Investigator# 33770
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wilhelmshaven : Site Reference ID/Investigator# 30466
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Winsen : Site Reference ID/Investigator# 53954
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Winsen : Site Reference ID/Investigator# 49296
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Winsen (Luhe) : Site Reference ID/Investigator# 53977
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wittlich : Site Reference ID/Investigator# 33780
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wittlich : Site Reference ID/Investigator# 33778
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wittlich : Site Reference ID/Investigator# 30175
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wolfsburg : Site Reference ID/Investigator# 33783
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wuerzburg : Site Reference ID/Investigator# 33718
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wuerzburg : Site Reference ID/Investigator# 33716
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wuerzburg : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Wuerzburg : Site Reference ID/Investigator# 49304
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Wuppertal :
An Observational Study of MabThera/Rituxan (Rituximab) and Alternative TNF-Inhibitors in Patients With Rheumatoid Arthritis and an Inadequate Response to a Single Previous TNF-Inhibitor
Wuppertal : Site Reference ID/Investigator# 35420
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Wuppertal : Site Reference ID/Investigator# 53917
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wuppertal : Site Reference ID/Investigator# 35418
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Wuppertal : Site Reference ID/Investigator# 49264
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Würzburg :
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Würzburg : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Zerbst : Site Reference ID/Investigator# 33864
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Zerbst : Site Reference ID/Investigator# 33862
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Zerbst : 59
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Zerbst : Site Reference ID/Investigator# 30468
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Zeven : Site Reference ID/Investigator# 33867
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Zeven : Site Reference ID/Investigator# 33865
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Zeven : Site Reference ID/Investigator# 30173
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Zwickau : Site Reference ID/Investigator# 33876
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Zwickau : Site Reference ID/Investigator# 33873
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Zwickau : Site Reference ID/Investigator# 33870
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Zwickau : Site Reference ID/Investigator# 30302
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Zwiesel : Site Reference ID/Investigator# 33880
Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice
Zwiesel : Site Reference ID/Investigator# 33878
Efficacy and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice
Zwiesel : Site Reference ID/Investigator# 30810
Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis
Greece
Agrinio : Site Ref # / Investigator 53645
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Agrinio : Site Ref # / Investigator 40873
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Argos : Site Ref # / Investigator 40746
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Athens :
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Athens :
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
View More »
Athens : Investigational Site Number 300001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Athens : Site Ref # / Investigator 40864
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Athens : Site Ref # / Investigator 40714
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Heraklion : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Heraklion : Investigational Site Number 300002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Kallithea : Site Ref # / Investigator 40755
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Katerini : Site Ref # / Investigator 40921
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Komotini : Site Ref # / Investigator 41024
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Lamia : Site Ref # / Investigator 40718
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Livadeia : Site Ref # / Investigator 40733
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Nea Smyrni : Site Ref # / Investigator 40740
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Pefki : Site Ref # / Investigator 40853
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Thessaloniki :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Thessaloniki :
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis
Thessaloniki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Thessaloniki : Investigational Site Number 300003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Thessaloniki : Site Ref # / Investigator 40716
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Thessaloniki : Site Ref # / Investigator 40713
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Thessaloniki : Site Ref # / Investigator 41030
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Triandria : Site Ref # / Investigator 41023
Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab
Hong Kong
Hong Kong :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Hungary
Baja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Baja : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Balassagyarmat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Balassagyarmat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Balatonfured : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
View More »
Balatonfured : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Balatonfured : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Balatonfured : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Bekescsaba : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Bekescsaba : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Budapest :
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
Budapest : MSD Magyarorszag Kft.
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)
Budapest :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Budapest : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Budapest : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Budapest : 18
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Budapest : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Budapest : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Budapest : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Budapest : Investigational Site Number 348006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Budapest : Investigational Site Number 348014 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Budapest : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Budapest : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Budapest : Location n°8 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Budapest : Location n°6 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Debrecen :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Debrecen : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Debrecen : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Debrecen : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Debrecen : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Debrecen : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Debrecen : Investigational Site Number 348003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Debrecen : Investigational Site Number 348010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Debrecen : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Debrecen : Location n°7 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Eger :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Eger : Investigational Site Number 348011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Eger : Location n°10 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Esztergom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Esztergom :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Esztergom : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Gy?r : Investigational Site Number 348013 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Gyor : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Gyula :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Gyula : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Kecskemet :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Kiskunhalas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kistarcsa :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Kistarcsa : Location n°9 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Mako : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Miskolc :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Nyiregyhaza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nyiregyhaza :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Nyiregyhaza : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Satoraljaujhely : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Sátoraljaújhely : Investigational Site Number 348005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sopron : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Szeged :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Szekesfehervar :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Szentes : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Szikszo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Szolnok :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Szombathely :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Szombathely : Investigational Site Number 348015 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Veszprem :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE)
Veszprem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Veszprem : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Veszprém : Investigational Site Number 348004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Zalaegerszeg : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Zalaegerszeg-pozva : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
India
Ahmedabad : Rathi Orthopaedic & Research Center
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Ahmedabad : Shalby Hospitals
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Ahmedabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Ahmedabad : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Bangalore : M S Ramaiah Medical College and Hospital
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Bangalore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bangalore : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Chandigarh :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy
Chennai : Chennai Meenakshi Multispeciality Hospital Limited
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Chennai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Coimbatore : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hyderabaad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hyderabad : Advance Rheumatology Clinic
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Hyderabad : Mahavir Hospital and Research Center
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Hyderabad : Sri Deepti Rheumatology Center
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Hyderabad : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Hyderabad : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Jaipur : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Jaipur : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Lucknow : Chhatrapati Shahuji Maharaj Medical University
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Lucknow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Lucknow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lucknow : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Madurai : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mangalore : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Mumbai :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy
Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mysore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nagpur : Sushrut Hospital Research Centre and PG Institute of Orthopaedics
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Nagpur : Vidarbha Arthritis & Superspeciality Clinic
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Nagpur : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Nellore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
New Delhi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
New Delhi :
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biologic DMARD and/or Anti-TNF Therapy
New Delhi : Investigative Site
GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy
Pune : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Secunderabad : Krishna Institute of Medical Sciences
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Secunderabad : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Secunderabad : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Surat : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Vadodara : Centre for Knee & Hip Surgery
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Vadodara : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Indonesia
Bandung :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
East Java :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Malang :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Yogyakarta :
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
Ireland
Cork : Site Ref # / Investigator 49402
A Study on the Prevalence of the Anti-MCV Anti-body in an Irish Rheumatoid Arthritis (RA) Population and the Impact of Biomarker Status on the Management of Irish Patients With Early RA
Dublin :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Dublin : 54
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Dublin 24 : Site Ref # / Investigator 22307
A Study on the Prevalence of the Anti-MCV Anti-body in an Irish Rheumatoid Arthritis (RA) Population and the Impact of Biomarker Status on the Management of Irish Patients With Early RA
Limerick : 32
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis
Israel
Ashkelon : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ashkelon : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Ashkelon : Barzilai Medical Center
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
Haifa : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Haifa : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
View More »
Kfar Saba : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Petah-tikva : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ramat Gan : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Rishon Lezion :
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS
Tel Aviv :
Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography
Tel Aviv : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Tel-hashomer : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Italy
Ancona :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Ancona : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Arenzano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Arenzano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bergamo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
View More »
Bergamo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Cagliari : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Catania : 08
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
Chieti : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Ferrara :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Ferrara : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Ferrara : 10
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
Florence : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Gazzi :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Jesi : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Jesi : 01
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
Legnano : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Messina : Location n°15 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Milano :
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis
Milano : Study site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Milano : 05
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
Milano : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Milano : Location n°16 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Modena :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Novara :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Palermo : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Parma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Pavia :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Pisa :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Pisa : Location n°17 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Prato :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Reggio Emilia : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Roma :
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-Inhibitor
Roma :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
San Cesario Di Lecce :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
San Giovanni Rotondo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
San Giovanni Rotondo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Saronno :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Siena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Siena : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Siena : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Torino : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Trieste :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Udine : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Valeggio Sul Minicio : 02
Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid Arthritis
Varese :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Verona :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Viterbo :
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
Japan
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Aichi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Aichi : Site Ref # / Investigator 65002
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 65014
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
View More »
Aichi : Site Ref # / Investigator 62159
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 64925
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 64971
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 65362
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 65382
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Aichi : Site Ref # / Investigator 67197
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Arakawa-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Asahikawa : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Bunkyo-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Bunkyo-Ku : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Chiba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Chiba : 102
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Chiba : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Chiba : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Chiba : Site Ref # / Investigator 62118
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Chiba : Site Ref # / Investigator 64977
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Chiba : Site Ref # / Investigator 62454
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Chiba : Site Ref # / Investigator 65394
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Chiba : Site Ref # / Investigator 62441
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Chiba : Site Ref # / Investigator 62155
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Chiba-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Chiba-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Chiyoda-ku : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Chiyoda-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Chubu Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Chugoku Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Ehime : Site Ref # / Investigator 57248
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Fuchu : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Fukui : Site Ref # / Investigator 62147
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukui : Site Ref # / Investigator 57603
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukui-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Fukuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Fukuoka : 114
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Fukuoka : 115
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Fukuoka : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Fukuoka : Site Ref # / Investigator 62110
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Fukuoka : Site Ref # / Investigator 47402
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Fukuoka : Site Ref # / Investigator 62156
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 62230
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 62232
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 64981
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 64962
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 65337
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 62143
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 65390
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka : Site Ref # / Investigator 62228
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukuoka-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Fukuoka-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Fukuoka-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Fukuoka-shi : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Fukushima : Site Ref # / Investigator 65307
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukushima : Site Ref # / Investigator 62157
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukushima : Site Ref # / Investigator 62234
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukushima : Site Ref # / Investigator 67176
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Fukusima : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Gifu : Site Ref # / Investigator 62096
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Gifu : Site Ref # / Investigator 67227
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Gifu : Site Ref # / Investigator 67267
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Goshogawara : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Gunma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Gunma : Site Ref # / Investigator 62088
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Gunma : Site Ref # / Investigator 65384
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Gunma : Site Ref # / Investigator 65392
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Gunma : Site Ref # / Investigator 64980
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Gunma : Site Ref # / Investigator 62146
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hamamatsu : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Hamamatsu : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Hamamatsu-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Hamamatsu-shi : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Hannan : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Higashi-Hiroshima-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Hiroshima : 113
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Hiroshima : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Hiroshima : Site Ref # / Investigator 62137
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hiroshima-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Hiroshima-city : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Hitachi-shi : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hokkaido : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hokkaido : Site Ref # / Investigator 65326
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 67192
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 64964
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 65335
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 62237
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 62238
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 62436
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido : Site Ref # / Investigator 62438
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hokkaido Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Hyogo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Hyogo : Site Ref # / Investigator 65044
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Hyogo : Site Ref # / Investigator 62440
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hyogo : Site Ref # / Investigator 64908
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hyogo : Site Ref # / Investigator 62239
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Hyogo : Site Ref # / Investigator 65349
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Ibaragi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Ibaraki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Ibaraki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Ibaraki : Site Ref # / Investigator 62116
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Ibaraki : Site Ref # / Investigator 62135
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ibaraki : Site Ref # / Investigator 62125
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ibaraki : Site Ref # / Investigator 64960
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ibaraki : Site Ref # / Investigator 62241
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ibaraki : Site Ref # / Investigator 62130
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Iizuka : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Iizuka-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Ishikawa : Site Ref # / Investigator 62244
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ishikawa : Site Ref # / Investigator 65368
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Itabashi : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Itabashi-ku : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kagoshima : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Kagoshima : Site Ref # / Investigator 62100
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Kagoshima : Site Ref # / Investigator 62247
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kagoshima : Site Ref # / Investigator 62150
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kagoshima : Site Ref # / Investigator 62456
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kakogawa : 120
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Kakogawa : Konan Kakogawa Hospital
Quality of Sleep in Patients With Rheumatoid Arthritis
Kamakura : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Kanagawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kanagawa : Site Ref # / Investigator 62099
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Kanagawa : Site Ref # / Investigator 62105
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Kanagawa : Site Ref # / Investigator 62119
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Kanagawa : Site Ref # / Investigator 62429
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 62253
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 62260
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 64906
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 65320
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 65397
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 62140
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 62258
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanagawa : Site Ref # / Investigator 67188
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kanto Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Kasama : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Kato-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Kawachinagano : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kawachinagano : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kawagoe-shi : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kawasaki-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kinki Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Kitakyushu : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kitakyushu-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Kitakyushu-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Kitakyusyu : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kitamoto : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kofu : 109
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Koto-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Koushi : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Kumamoto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kumamoto : 118
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Kumamoto : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kumamoto : Site Ref # / Investigator 62108
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Kumamoto : Site Ref # / Investigator 65387
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kumamoto : Site Ref # / Investigator 65019
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kumamoto : Site Ref # / Investigator 62443
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kumamoto-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kurashiki : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kurashiki-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Kurume : 116
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Kurume : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kyoto : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Kyoto : Site Ref # / Investigator 62445
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kyoto : Site Ref # / Investigator 67178
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kyoto : Site Ref # / Investigator 65395
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kyoto : Site Ref # / Investigator 64955
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Kyushu Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Matsuyama : 121
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Meguro-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mie : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mie : Site Ref # / Investigator 65356
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Mie : Site Ref # / Investigator 65354
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Miyagi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Miyagi : Site Ref # / Investigator 67240
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Miyagi : Site Ref # / Investigator 62430
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyagi : Site Ref # / Investigator 62432
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyagi : Site Ref # / Investigator 62151
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyazaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Miyazaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Miyazaki : Site Ref # / Investigator 62085
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Miyazaki : Site Ref # / Investigator 62152
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyazaki : Site Ref # / Investigator 62262
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyazaki : Site Ref # / Investigator 65316
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Miyazaki-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Musashimurayama-shi : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Nagano : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nagano : Site Ref # / Investigator 62098
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Nagano : Site Ref # / Investigator 62120
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Nagano : Site Ref # / Investigator 62128
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nagano : Site Ref # / Investigator 65343
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nagano-Shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Nagano-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Nagaoka : 107
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Nagasaki : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nagasaki : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Nagasaki : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Nagasaki : Site Ref # / Investigator 62113
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Nagasaki : Site Ref # / Investigator 62264
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nagasaki : Site Ref # / Investigator 62160
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nagasaki : Site Ref # / Investigator 62131
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nagasaki-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Nagoya : 110
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Nagoya : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Nagoya : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Nagoya-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Nagoya-shi, 23 : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Nara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Nara : Site Ref # / Investigator 62086
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Nara : Site Ref # / Investigator 64904
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Nara : Site Ref # / Investigator 65005
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Narashino : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Narita : 103
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Niigata : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Niigata : Site Ref # / Investigator 65052
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Niigata : Site Ref # / Investigator 57245
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Niigata : Site Ref # / Investigator 64954
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Ohita : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Ohmura : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Oita : 119
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Oita : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Oita : Site Ref # / Investigator 65010
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Oita : Site Ref # / Investigator 62265
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Oita : Site Ref # / Investigator 62266
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Okayama : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Okayama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Okayama : 112
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Okayama : Site Ref # / Investigator 62083
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Okayama : Site Ref # / Investigator 67269
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Okayama : Site Ref # / Investigator 62104
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Okayama : Site Ref # / Investigator 62459
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okayama : Site Ref # / Investigator 62462
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okayama : Site Ref # / Investigator 62267
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okayama : Site Ref # / Investigator 62268
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okayama : Site Ref # / Investigator 65308
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Okinawa : Site Ref # / Investigator 62109
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Omura-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Omura-shi : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Osaka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Osaka : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Osaka : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Osaka : Site Ref # / Investigator 57247
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Osaka : Site Ref # / Investigator 65309
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 64978
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 64922
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 67179
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65358
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 62269
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 62270
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 62271
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 62452
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65344
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65331
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65334
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65352
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65367
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 65369
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 67198
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka : Site Ref # / Investigator 62136
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Osaka-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Saga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Saga : Site Ref # / Investigator 65324
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Sagamihara : 106
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Sagamihara : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Sagamihara : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sagamihara-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Saitama : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Saitama : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Saitama : Site Ref # / Investigator 65051
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Saitama : Site Ref # / Investigator 65046
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Saitama : Site Ref # / Investigator 67243
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Saitama : Site Ref # / Investigator 62124
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 62272
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 62126
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 62139
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 65339
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 64939
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Saitama : Site Ref # / Investigator 65304
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Sapporo : 100
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Sapporo : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Sapporo : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sapporo : Site Ref # / Investigator 62082
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Sapporo-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sapporo-Shi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Sasebo : 117
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Sasebo : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sasebo-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Sasebo-shi : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Sasebo-shi : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Sasebo-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Sawara-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sendai : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Sendai : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Sendai : 392001001
Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis
Shiga : Site Ref # / Investigator 62428
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Shikoku Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Shimane : Site Ref # / Investigator 62427
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Shinjuku : Research Site
Evaluation of Safety and Effectiveness of Fostamatinib Compared to Placebo in Patients in Asia With Rheumatoid Arthritis
Shinjuku-ku : Research Site
A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid Arthritis
Shinjuku-ku : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Shinjuku-Ku : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Shinjuku-ku, Tokyo : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Shinjyuku-ku : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Shizuoka : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Shizuoka : Site Ref # / Investigator 57246
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Shizuoka : Site Ref # / Investigator 62102
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Shizuoka : Site Ref # / Investigator 62274
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Shizuoka : Site Ref # / Investigator 65346
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Shizuoka : Site Ref # / Investigator 65338
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Shizuoka-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Taishaku : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Takasaki : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Tochigi : Site Ref # / Investigator 62101
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tochigi : Site Ref # / Investigator 65329
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tochigi : Site Ref # / Investigator 62425
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tohoku Region :
Efficacy Confirmation Study of CDP870 in Early Rheumatoid Arthritis
Tokorozawa-city : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Tokushima : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tokyo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tokyo : Site Ref # / Investigator 65048
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tokyo : Site Ref # / Investigator 65053
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tokyo : Site Ref # / Investigator 62103
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tokyo : Site Ref # / Investigator 62107
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tokyo : Site Ref # / Investigator 67244
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Tokyo : Site Ref # / Investigator 64903
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 64990
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 65372
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 62446
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 62455
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 62275
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 62276
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 62277
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 65348
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 65327
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tokyo : Site Ref # / Investigator 50022
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tomakomai : 101
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Tomigusuku-Shi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Tonami : 108
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Toshima-Ku : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Tottori : Site Ref # / Investigator 62448
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Toyama : Site Ref # / Investigator 65045
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Toyama : Site Ref # / Investigator 57249
Special Investigation in Patients With Rheumatoid Arthritis (HOPE3 Study Follow up Survey (P12-069))
Toyama : Site Ref # / Investigator 62279
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Toyama : Site Ref # / Investigator 62431
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Tsu : 111
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Tsukuba : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Ureshino : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Yamagata : Site Ref # / Investigator 64928
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yamaguchi : Site Ref # / Investigator 62281
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yamaguchi : Site Ref # / Investigator 65365
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yamaguchi : Site Ref # / Investigator 62134
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yamaguchi : Site Ref # / Investigator 62162
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yamanashi : Site Ref # / Investigator 62282
Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment)
Yokohama : 105
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Yotsukaido : Novartis Investigative Site
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Yotukaido : 104
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Yotukaidou : Pfizer Investigational Site
Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Korea, Republic of
Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Busan :
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
Busan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Busan : Investigational Site Number 410006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
View More »
Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Daegu : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Daegu : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Daegu : Investigational Site Number 410004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Daegu : Investigational Site Number 410013 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Daejeon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Daejeon :
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
Daejeon : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Daejeon : 200
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Daejeon : Investigational Site Number 410005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Daejeon : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Gangnam-Gu : 205
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Gwang Ju :
An Observational Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis And Inadequate Response Or Intolerance to a First Anti-TNF Alpha Therapy
Gwangju : Investigational Site Number 410010 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Gyeonggi-do :
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Incheon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Incheon : Investigational Site Number 410009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Incheon : Investigational Site Number 410001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Jeonju : Investigational Site Number 410011 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Jung-gu : 201
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Seongdong-gu : 202
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Seongnam-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Seongnam-Si : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Seoul :
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
Seoul : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Seoul : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Seoul : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Seoul : 203
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Seoul : 204
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
Seoul : Investigational Site Number 410012 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Seoul : Investigational Site Number 410002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Seoul : Investigational Site Number 410003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Seoul : Investigational Site Number 410007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Seoul : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Seoul : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Seoul : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Suwon : Investigational Site Number 410008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Suwon-City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Latvia
Liepaja : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Riga : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Valmiera : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Lebanon
Beirut :
An Observational Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis
Lithuania
Alytus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Alytus : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kaunas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kaunas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kaunas : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
View More »
Kaunas : Investigational Site Number 440001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Klaipeda : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Klaipedos : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Panevezys : Location n°30 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Siauliai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Siauliai : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Siauliai : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Vilnius : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Vilnius : Investigational Site Number 440002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Vilnius : Location n°28 Updated
Validation Study of RA-INF-Dx, a Multigene Molecular Test Used to Predict Non-Response to INfliximab Therapy
Malaysia
Batu Caves : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Batu Caves : Site Ref # / Investigator 36098
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Batu Caves : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Ipoh : Site Ref # / Investigator 57914
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Ipoh : Investigational Site Number 458001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
View More »
Johor Bahru : Site Ref # / Investigator 57923
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Klang : Site Ref # / Investigator 67602
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Kota Bahru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Kota Bahru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kota Kinabalu : Site Ref # / Investigator 57925
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Kuala Lumpur : Site Ref # / Investigator 57916
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Kuantan : Site Ref # / Investigator 57928
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Kuantan Pahang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Kuantan Pahang : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Kuching : Site Ref # / Investigator 57924
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Kuching : Investigational Site Number 458002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Melaka : Site Ref # / Investigator 57927
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Patrajaya : Site Ref # / Investigator 57915
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Penang : Site Ref # / Investigator 57913
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Perak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Putrajaya : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Putrajaya : Investigational Site Number 458003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Sarawak : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Serdang : Site Ref # / Investigator 57926
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Seremban : Site Ref # / Investigator 57922
A Study of Rheumatoid Arthritis Patients on Adalimumab to Evaluate Quality of Life Variables, Effects on Work Productivity and Functional Outcomes in Malaysia
Mexico
Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Aguascalientes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Barrio San Mateo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Barrio San Mateo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
View More »
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Chihuahua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Chihuahua : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Chihuahua : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Chihuahua : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Chihuahua : Site Ref # / Investigator 55265
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Culiacan :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Culiacan : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
D.f. : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
DF : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Durango : Investigational Site Number 484008 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Guadalajara :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Guadalajara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Guadalajara : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Guadalajara : Investigational Site Number 484002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Guadalajara : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Guadalajara : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Leon :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Merida : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Merida : Investigational Site Number 484004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Merida : Investigational Site Number 484009 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Metepec : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Metepec : Investigational Site Number 484007 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mexicali : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mexico : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Mexico City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Mexico City : Investigational Site Number 484003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Mexico City : Site Ref # / Investigator 55268
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Mexico City : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Mexico Ctiy :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Mexico, D.F. : Investigational Site Number 484001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Monterrey : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Monterrey : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Monterrey : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Monterrey : Investigational Site Number 484005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Monterrey : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Morelia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Morelia : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Obregon :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Obrergon : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Obrergon : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Queretaro : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Queretaro : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Saltillo :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Saltillo : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Saltillo : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
San Luis Potosi : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
San Luis Potosi : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
San Luis Potosi : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
San Luis Potosi : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
San Luis Potosi : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tijuana : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tijuana : Local Institution
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
Tlalpan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Torreon :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Monaco
Monaco :
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)
Netherlands
Alkmaar :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Amersfoort :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Amsterdam : Academic Medical Center, University of Amsterdam
Long Term Extension Study For SPM-005 Participants
Amsterdam : 009
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Amsterdam : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
View More »
Amsterdam : Academic Medical Center, University of Amsterdam
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis
Beek en Donk : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Boxtel : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Den Helder :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Dordrecht : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Gouda :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Groningen :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Haarlem :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Hoofddorp :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Hoogwoud : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Leeuwarden :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Leids : Nycomed Investigational Site
A Trial to Evaluate the Safety and Tolerability of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis
Nijmegen :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Nijmegen : 012
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Nijverdal : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
's-Hertogenbosch : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Sneek :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Spijkenisse : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
Stationsweg 163 : PRA International (PRA)
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
Utrecht :
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis
Utrecht : 010
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Vlodrop : Research Site
Descriptive Study in Patients Treated With Vimovo™, Including Registration of the Physicians' Prescribing Patterns
New Zealand
Auckland :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Christchurch : Investigational Site Number 554004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
View More »
Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Rotorua : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Rotorua : Investigational Site Number 554002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Tauranga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Tauranga : Investigational Site Number 554003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Timaru : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Timaru : Investigational Site Number 554001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Norway
Ålesund : Helse Sunnmøre HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Bergen : Helse Bergen HF, Haukeland University Hospital, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Drammen : Vestre Viken HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Haugesund : Haugesund Sanitetsforening Revmatismesykehus
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Kristiansand : Revmatologene bendvold/Dovland
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
View More »
Kristiansand : Sørlandet Sykehus HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Kristiansand : Investigational Site Number 578004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lillehammer : Lillehammer Hospital for Rheumatic Diseases
Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment
Moss : Sykehuset Østfold HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Oslo : Diakonhjemmet Sykehus AS, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Sandvika : Martina Hansens Hospital AS
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Tønsberg : Investigational Site Number 578006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Tromsø : Universitetssykehuset Nord-Norge HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Trondheim : St Olavs Hospital HF, Dept. of Rheumatology
Aiming for Remission in Rheumatoid Arthritis (RA) - the ARCTIC Trial
Peru
Philippines
Makati City : Merck Sharp & Dohme (I.A.) Corporation
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM2 EXT 1)
Poland
Bialystok : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Bialystok : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Bialystok : Investigational Site Number 616002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bialystok : Investigational Site Number 616003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Bydgoszcz : Oddział Kliniczny Reumatologii i Ukladowych Chorob Tkanki Lacznej
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
View More »
Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Bydgoszcz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Bytom : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Bytom : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Chelm Slaski : Centrum Medyczne MEDENS S.C. Grupowa Praktyka Lekarska
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Chelm Slaski : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Czestochowa : Specjalistyczna Praktyka Lekarska Joanna Badowska
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Dzialdowo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Dzialdowo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Elblag : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Gdynia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Gdynia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Grodzisk Mazowiecki : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Grodzisk Mazowiecki : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Katowice : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Katowice : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Krakow : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Krakow : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Krakow : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Krakow : Investigational Site Number 616001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lublin : NZOZ Reumed
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Lublin :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Lublin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Lublin : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Lublin : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Lublin : Investigational Site Number 616005 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Nadarzyn : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Plock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Plock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Poznan :
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis
Poznan : Study Site
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
Poznan : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Poznan : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Poznan : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Torun : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Torun : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Torun : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Torun : Investigational Site Number 616006 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study in Patients With Rheumatoid Arthritis
Warsaw : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
An Open Label Study for Patients With Rheumatoid Arthritis
Warszawa : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Warszawa : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Warszawa : Investigational Site Number 616004 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Warszawa : 019
Magnetic Resonance Image Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA)
Warszawa : Local Institution
Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate
Warszawa : Pfizer Investigational Site
Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis
Wloszczowa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate
Wroc#Aw : Local Institution
Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)
Wroclaw : Wojewodzki Zespol Specjalistycznej Opieki Zdrowotnej
A Clinical Trial to Study the Effects of Revamilast in Patients With Rheumatoid Arthritis
Wroclaw : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Wroclaw : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Zyrardow : Research Site
Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)
Zyrardow : Research Site
Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)
Portugal
Almada :
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arhtritis and an Inadequate Response to Non-biological DMARDs
Aveiro : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Aveiro : Investigational Site Number 620003 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lisboa :
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Sero-Positive Rheumatoid Arthritis Who Are Non-Reponders or Intolerant to a Single TNF-Inhibitor (PORTSMAB)
Lisboa : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
View More »
Lisboa : Investigational Site Number 620001 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lisboa : Investigational Site Number 620002 Updated
Evaluation of SAR153191(REGN88)(Sarilumab) on Top of Methotrexate in Rheumatoid Arthritis Patients
Lisbon : Site Ref # / Investigator 55204
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
Porto : Hospital de Santo Antonio
An Electronic Data Capture Study to Assess the Long-term Performance of the DePuy PROXIMA™ Hip in Primary Total Hip Replacement
Porto : Research Site
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate and Have Had Inadequate Response to Single TNF-alpha Antagonist
Puerto Rico
Caguas : Site Ref # / Investigator 55487
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
San Juan : Site Reference ID/Investigator# 38691
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
San Juan : Pfizer Investigational Site Updated
Effects of Tasocitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA).
Vega Baja : Site Reference ID/Investigator# 60851
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
Vega Baja : Site Ref # / Investigator 54942
Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)
